

# FISH & RICHARDSON P.C.



225 Franklin Street  
Boston, Massachusetts  
02110-2804

Telephone  
617 542-5070

Facsimile  
617 542-8906

Web Site  
www.fr.com

January 6, 1999

Attorney Docket No.: 07236/013004

## Box Patent Application

Assistant Commissioner for Patents  
Washington, DC 20231

Presented for filing is a new continuation patent application of:

Applicant: DOUGLAS A. TRECO, MICHAEL W. HEARTLEIN,  
BRIAN M. HAUGE AND RICHARD F SELDEN  
Title: TRANSKARYOTIC PRODUCTION AND DELIVERY OF  
DNASE

The prior application is assigned of record to Transkaryotic Therapies, Inc., a Delaware corporation, by virtue of an assignment submitted to the Patent and Trademark Office for recording on April 26, 1995 at 7450/0993.

Enclosed are the following papers, including those required to receive a filing date under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	68
Claims	10
Abstract	1
Declaration	3
Drawing(s)	30

### Enclosures:

- Preliminary amendment, 1 page.
- Postcard.

"EXPRESS MAIL" Mailing Label Number EL245412276 US

Date of Deposit January 6, 1999

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231

Douglas L. Roache  
Douglas L. Roache

01/06/99



Frederick P. Fish  
1855-1930  
W.K. Richardson  
1859-1951

BOSTON

NEW YORK

SILICON VALLEY

SOUTHERN CALIFORNIA

TWIN CITIES

WASHINGTON, DC

January 6, 1999

Page 2

This application is a continuation (and claims the benefit of priority under 35 USC 120) of U.S. Application Serial No. 09/012,364, filed January 23, 1998, which is a divisional of Application Serial No. 08/406,030, filed March 17, 1995, which is a CIP of Application Serial No. 08/243,391, filed May 13, 1994, now U.S. Patent No. 5,641,670, which is a CIP of Application Serial No. 07/985,586, filed December 3, 1992, and is also a CIP of Application Serial No. 07/911,533, filed July 10, 1992, and is also a CIP of Application Serial No. 07/787,840, filed November 5, 1991, and is also a CIP of Application Serial No. 07/789,188, filed November 5, 1991. This application also claims priority from PCT/US93/11704, filed December 2, 1993 and PCT/US92/09627, filed November 5, 1992. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.

This application is entitled to small entity status. Small entity status from a previous application is still proper.

The filing fee, based on claims cancelled and/or added in the attached preliminary amendment, is calculated below.

Basic filing fee	380.00
Total claims in excess of 20 times \$11.00	0.00
Independent claims in excess of 3 times \$39.00	0.00
Fee for multiple dependent claims	0.00
Total filing fee:	\$ 380.00

Under 37 CFR §1.53(d), no filing fee is being paid at this time. Please apply any other required fees, **EXCEPT FOR THE FILING FEE**, to Deposit Account No. 06-1050, referencing the attorney docket number shown above.

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 617/542-5070.

FISH & RICHARDSON P.C.

January 6, 1999


Page 3

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Send all correspondence to:

Janis K. Fraser, Ph.D., J.D.  
Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Janis K. Fraser", is written over the typed name and registration number. The signature is fluid and cursive, with a large loop at the beginning and end.

Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Enclosures

348695.B11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Douglas A. Treco et al.                      Art Unit:  
Serial No.:    Examiner:  
Filed : January 6, 1999  
Title : TRANSKARYOTIC PRODUCTION AND DELIVERY OF DNASE



**Box Continuation Application**  
Assistant Commissioner for Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Claims:

Cancel claims 22-37.


REMARKS

This amendment is being filed together with a continuation application. Independent claim 1 remains pending in this application.

Respectfully submitted,

Date:

Jan. 6, 1999

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804


Telephone: 617/542-5070  
Facsimile: 617/542-8906  
348392.B11

"EXPRESS MAIL" Mailing Label Number EL2454/12276 US

Date of Deposit

JANUARY 6, 1999

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

  
Douglas W. Roache



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Douglas A. Treco et al.                      Art Unit:  
Serial No.:    Examiner:  
Filed : January 22, 1998  
Title : TRANSKARYOTIC PRODUCTION AND DELIVERY OF DNASE

**Box Patent Application**

Assistant Commissioner for Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Specification:

On page 1, line 5, after "This application" please insert --is a divisional of application serial number 08/406,030, filed March 17, 1995, which--; and on line 7, after "1994," insert --now U.S. Pat. No. 5,641,670,--.

In the Claims:

Cancel claims 1-20 and 38-57 without prejudice.

REMARKS

Claims 21-37 are now pending in the application. These claims correspond to Group IV of the restriction requirement mailed May 29, 1996 in USSN 08/406,030, parent to the present application. No new matter is added by the above amendments.

"EXPRESS MAIL" Mailing Label Number EM04095434505

Date of Deposit January 22, 1998


I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Lisa G Gray  
Lisa G Gray

Please charge any fees, or make any credits, to Deposit  
Account No. 06-1050.

Respectfully submitted,

Date: 22 Jan. 1998

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804

Telephone: 617/542-5070  
Facsimile: 617/542-8906  
284787.B11

TRANSKARYOTIC PRODUCTION AND DELIVERY OF DNASE

Related Applications

5 This application is a Continuation-In-Part of U.S.  
 Patent Application, Serial No. 08/243,391, filed May 13,  
 1994, which is a Continuation-In-Part of U.S. Patent  
 Application, Serial No. 07/985,586, filed December 3, 1992,  
 and is also a Continuation-In-Part of U.S. Patent  
 10 Application, Serial No. 07/911,533, filed July 10, 1992, and  
 is also a Continuation-In-Part of U.S. Patent Application,  
 Serial No. 07/787,840, filed November 5, 1991, and is also a  
 Continuation-In-Part of U.S. Patent Application, Serial No.  
 07/789,188, filed November 5, 1991, all of which are  
 15 incorporated herein by reference. This application also  
 claims priority and is related to PCT/US93/11704, filed  
 December 2, 1993, and is also related to PCT/US92/09627,  
 filed November 5, 1992. The teachings of PCT/US93/11704 and  
 PCT/US92/09627 are incorporated herein by reference.

Background of the Invention

20 Current approaches to treating disease by administering  
 therapeutic proteins include in vitro production of  
 therapeutic proteins for conventional pharmaceutical  
 delivery (e.g. intravenous, subcutaneous, or intramuscular  
 25 injection, or by intranasal or intratracheal aerosol  
 administration) and, more recently, gene therapy.

One protein which may be useful in the treatment of  
 platelet disorders is thrombopoietin (TPO). Platelets are  
 small (2-3 microns in diameter) anucleated cells which play  
 30 an important role in primary hemostasis by adhering to and  
 aggregating at sites of vascular damage. In addition,  
 platelets release factors which are important components of  
 the blood coagulation, inflammation, and wound healing

pathways. Patients with very low levels of circulating platelets (thrombocytopenia) exhibit bleeding into superficial sites (e.g. skin, mucous membranes, genitourinary tract, and gastrointestinal tract) as a result of mild trauma, and are at risk for death from catastrophic hemorrhage occurring spontaneously or resulting from trauma. The physiologic role of platelets and the etiology of platelet disorders have been described (cf. *Hematology: Clinical and Laboratory Practice*, Eds. R.L. Bick et al., pp. 1337-1389, Mosby, St. Louis (1993); *Harrison's Principles of Internal Medicine*, Eds. J.D. Wilson et al., 11th Ed., pp. 1500-1505, McGraw Hill, New York, 1991).

Thrombocytopenia may be caused by decreased production of platelets by the bone marrow, increased sequestration of platelets in the spleen, or accelerated platelet destruction. Decreased production of platelets by the bone marrow may result from destruction of hematopoietic precursor cells by irradiation or treatment with cytotoxic agents during therapy for cancer. In addition, alcohol, estrogens, and thiazide diuretics can suppress platelet production (drug-induced thrombocytopenia). Furthermore, infiltration of the bone marrow by malignant cells and the disorders congenital amegakaryocytic hypoplasia and thrombocytopenia with absent radii (TAR syndrome) can result in decreased platelet production.

Increased splenic sequestration of platelets may occur as a result from splenomegaly associated with a variety of conditions, including liver disease, infiltration of the spleen with tumor cells as in myeloproliferative or lymphoproliferative disorders, and Gaucher's disease.

Accelerated platelet destruction and thrombocytopenia may be caused by vasculitis, hemolytic uremic syndrome, disseminated intravascular coagulation, and the presence of

intravascular prosthetic devices such as cardiac valves. In addition, certain viral infections, drugs, and autoimmune disorders lead to immunologic thrombocytopenia in which platelets become coated with antibody, immune complexes, or complement and are rapidly cleared from the circulation. A number of drugs can elicit an immune response leading to immunologic thrombocytopenia, including sulfathiazole, novobiocin, para-aminosalicylate, quinidine, quinine, carbamazepine, digitoxin, arsenical drugs, and methyldopa.

Thrombocytopenia is currently treated most readily by transfusion with platelet concentrates, although corticosteroid therapy or plasmapheresis can be effective in immunologic thrombocytopenia. Treatment with platelet concentrates is severely limited by availability of suitable donors and the risk of transmission of blood-borne infectious diseases.

As an alternative to transfusion therapy, platelet deficiencies could be treated with hematopoietic growth factors which promote proliferation and maturation of megakaryocytes, the nucleated progenitor cells from which platelets are derived. Recently, cDNA clones were isolated which encode the human, mouse, and dog analogs of a protein purified from aplastic porcine plasma which displays megakaryocytopoietic activity (de Sauvage, F.J. et al. *Nature* 369:533-538 (1994); Lok, S. et al. *Nature* 369:565-568 (1994); Bartley, T.D. et al. *Cell* 77:1117-1124 (1994)). The encoded protein, termed thrombopoietin (TPO), stimulates proliferation and maturation of megakaryocytes and induces platelet production in vivo upon injection into experimental animals.

Methods for the production and delivery of other proteins with therapeutic properties are desirable. For example, it has been demonstrated that recombinant

β-interferon is an effective medication for treatment of exacerbations in patients with relapsing-remitting multiple sclerosis (MS; see Kelley, C.L. and Smeltzer, S.C. *J. Neuroscience Nursing* 26:52-56 (1994)). Furthermore, it has been reported that β-interferon isolated from non-transfected cultured human fibroblasts may be an effective means for preventing the progression of acute non-A, non-B hepatitis to chronic disease (Omata, M. et al., *Lancet* 338:914-915 (1991)).

As another example, it has been demonstrated that recombinant human DNase I is an effective agent for reducing the viscosity of sputum from cystic fibrosis (CF) patients (Shak, S. et al., *Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)) and for improving pulmonary function and decreasing exacerbations of respiratory disease in CF patients (Fuchs, H.J. et al., *New Engl. J. Med.* 331:637-642 (1994)). It has been further suggested that DNase I may be effective in improving respiratory function in patients with other respiratory diseases, such as chronic bronchitis and pneumonia (Shak, S. et al., op. cit.).

While TPO, β-interferon, and DNase I are useful, for example, in the treatment of thrombocytopenia, MS, and CF, respectively, production of therapeutic proteins using genetic engineering technology as taught in the prior art is limited to conventional recombinant DNA methods, in which the recombinant protein is purified from mammalian cells expressing an exogenous cloned gene or cDNA under the control of a suitable promoter. The exogenous DNA encoding the protein of interest is introduced into cells in the form of a viral vector, circular plasmid DNA, or linear DNA fragment. Chinese Hamster Ovary (CHO) cell lines and their derivatives (Gottesman, M. M. *Meth. Enzymol.* 151:3-8 (1987) or mouse cell lines, such as NSO (Galfre, G. and Milstein,

C., *Meth. Enzymol.* 73(B): 3-46 (1981)) or P3X63Ag8.653  
(Kearney, J. et al. *J. Immunol.* 123: 1548-1550 (1979)) are  
commonly used, and the production of human therapeutic  
proteins is thus accomplished by expression and purification  
5 of the protein from a cell of non-human origin.

In many cases, it is desirable to produce human  
therapeutic proteins in a human cell, for example, when it  
is desired that the glycosylation pattern of the protein be  
similar to patterns normally found on human cells. In  
10 addition, the expression of human proteins in human cells is  
important in the development of gene therapy methods, in  
which a patient's cells are engineered to produce a desired  
therapeutic protein to alleviate the symptoms or cure a  
disease.

15 Clearly, the development of novel methods for the  
production of these human proteins in human cells would be  
of benefit to patients, through the availability of a wider  
range of products with therapeutic effectiveness. One  
approach proposed by scientists in the field for  
20 accomplishing this goal is to use homologous recombination,  
or gene targeting, to introduce a cloned, exogenous  
regulatory element (i.e. a promoter and/or enhancer) into a  
cell's genome at a pre-selected site such that the  
regulatory element activates expression of a nearby gene,  
25 ultimately resulting in production of the protein encoded by  
that gene. This approach has been suggested in U.S. Patent  
No. 5,272,071 and in foreign patent applications WO  
91/06666, WO 91/06667 and WO 90/11354.

#### Summary of the Invention

30 Described herein are new methods for producing TPO,  
DNase I, and  $\beta$ -interferon through the generation of novel  
transcription units within a cell's genome, methods which

5 differ dramatically from those in the art and represent a  
major advance in the ability to manipulate expression in  
mammalian cells. The methods are based on the fact that an  
exogenous regulatory sequence, an exogenous exon, either  
coding or non-coding, and a splice-donor site can be  
introduced into a preselected site in the genome by  
homologous recombination. The resulting cells are referred  
to as targeted or homologously recombinant cells. The  
introduced DNA is positioned such that transcripts under the  
control of the exogenous regulatory region include both the  
exogenous exon and endogenous exons present in either the  
*TPO*, *DNase I*, or  $\beta$ -interferon genes, resulting in  
transcripts in which the exogenous and endogenous exons are  
operatively linked. The novel transcription units produced  
by homologous recombination allow *TPO*, *DNase I*, or  
 $\beta$ -interferon to be produced in human cells using the  
naturally-occurring endogenous exons encoding these proteins  
without introducing any portion of the coding sequences of  
the cognate genes. The present invention further relates to  
improved materials and methods for both the in vitro  
production of *TPO*,  $\beta$ -interferon, and *DNase I* and for the  
production and delivery of *TPO*,  $\beta$ -interferon, and *DNase I* by  
gene therapy.

The methods of the present invention teach the  
production of *TPO*,  $\beta$ -interferon, or *DNase I* by gene  
activation, in which the coding DNA sequence of the  
corresponding protein is not introduced into a cell by  
transfection of exogenous DNA encoding the protein.  
Instead, noncoding sequences upstream of one of these genes  
or coding or noncoding sequences within the genes are  
manipulated by gene targeting to create a novel  
transcription unit which expresses *TPO*,  $\beta$ -interferon, or  
*DNase I*. It is a purpose of this invention to define



sequences upstream of the *TPO*,  $\beta$ -interferon, or *DNase I* genes, non-coding sequences (introns and 5' non-translated sequences) within the human *TPO*,  $\beta$ -interferon, or *DNase I* genes, and methods for utilizing these sequences for the production of *TPO*,  $\beta$ -interferon, or *DNase I*.

The methods described herein teach production of *TPO*,  $\beta$ -interferon, or *DNase I* proteins, by the generation of novel genes in which exogenous and endogenous exons are operatively linked. As a result of introduction of exogenous components into the chromosomal DNA of a cell, the expression of the protein encoded by the endogenous gene is activated. Other forms of altered gene expression may be envisioned, such as increasing expression of a gene which is expressed in the cell as obtained, changing the pattern of regulation or induction such that it is different than occurs in the cell as obtained, and reducing (including eliminating) expression of a gene which is expressed in the cell as obtained. For example, it may be desirable to perform in vitro protein production or gene therapy to produce a protein other than *TPO*, *DNase I*, or  $\beta$ -interferon using a cell type that naturally produces one of these proteins. In these settings, it would be desirable to eliminate expression of *TPO*, *DNase I*, or  $\beta$ -interferon.

The present invention further relates to DNA constructs useful in the method of activation of the *TPO*,  $\beta$ -interferon, or *DNase I* genes. The DNA constructs comprise: (a) targeting sequences; (b) a regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site. The targeting sequence in the DNA construct is derived from chromosomal DNA lying within and/or upstream of the desired gene and directs the integration of elements (a) - (d) into the chromosomal DNA in a cell such that the elements (b) - (d) are operatively linked to sequences of the desired

endogenous gene. In another embodiment, the DNA constructs comprise: (a) a targeting sequence, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence in the DNA construct is derived from chromosomal DNA lying within and/or upstream of the desired gene and directs the integration of elements (a) - (f) such that the elements of (b) - (f) are operatively linked to the desired endogenous gene. The targeting sequence is homologous to the preselected site within or upstream of the *TPO*,  $\beta$ -interferon, or *DNase I* genes in the cellular chromosomal DNA with which homologous recombination is to occur. In the construct, the exon is generally 3' of the regulatory sequence and the splice-donor site is 3' of the exon. Constructs of this type are disclosed in pending U.S. patent applications U.S.S.N. 07/985,586 and U.S.S.N. 08/243,391, all of which are incorporated herein by reference.

The following serves to illustrate two embodiments of the present invention, in which the sequences upstream of the *TPO* gene are altered to allow expression of *TPO* in primary, secondary, or immortalized cells which do not express *TPO* in detectable quantities in their untransfected state as obtained. In embodiment 1 (Figure 1), the targeting construct contains two targeting sequences. Both the first and second targeting sequences are homologous to sequences upstream of the *TPO* coding region, with the first targeting sequence 5' of the second targeting sequence. The targeting construct also contains a regulatory region, an exon (which in this case, comprises noncoding sequences and begins at a CAP site) and an unpaired splice-donor site. The homologous recombination event that generates the novel transcription unit producing *TPO* is shown in Figure 1.

In embodiment 2 (Figure 2), the targeting construct also contains two targeting sequences. The first targeting sequence is homologous to sequences upstream of the endogenous TPO coding region, and the second targeting sequence is homologous to the second intron of the TPO gene. The targeting construct also contains a regulatory region, an exon (in this case a coding exon derived from the human growth hormone (hGH) gene) and an unpaired splice-donor site. The homologous recombination event that generates the novel transcription unit producing TPO is shown in Figure 2.

In these two embodiments, the products of the targeting events are novel transcription units which generate a mature mRNA in which an exogenous exon is positioned upstream of exon 2 (Embodiment 1) or exon 3 (Embodiment 2) of the endogenous TPO gene. The product of transcription, splicing, translation, and post-translational cleavage of the signal peptide is mature TPO. Embodiments 1 and 2 differ with respect to the relative positions of the regulatory sequences of the targeting construct that are inserted and the specific pattern of splicing that needs to occur to produce the final, processed transcript.

The invention further relates to a method of producing TPO,  $\beta$ -interferon, or DNase I in vitro or in vivo through introduction of a construct as described above into host cell chromosomal DNA by homologous recombination to produce a homologously recombinant cell. The homologously recombinant cell is then maintained under conditions which will permit transcription, translation and secretion of TPO,  $\beta$ -interferon, or DNase I.

The present invention also relates to cells, such as homologously recombinant primary or secondary cells (i.e., non-immortalized cells) and homologously recombinant immortalized cells, useful for producing TPO,  $\beta$ -interferon,

or DNase I, methods of making such cells, methods of using the cells for in vitro protein production, and methods of gene therapy. Homologously recombinant cells of the present invention are of vertebrate origin, particularly of mammalian origin, and even more particularly of human origin. Homologously recombinant cells produced by the method of the present invention contain exogenous DNA which causes the homologously recombinant cells to express a desired gene at a higher level or with a pattern of regulation or induction that is different than occurs in the corresponding cell that has not undergone homologous recombination.

In one embodiment, the activated *TPO*,  $\beta$ -interferon, or *DNase I* gene can be further amplified by the inclusion of an amplifiable selectable marker gene which has the property that cells containing amplified copies of the selectable marker gene can be selected for by culturing the cells in the presence of the appropriate selectable agent. The activated gene is amplified in tandem with the amplifiable selectable marker gene. Cells containing many copies of the activated gene are useful for in vitro protein production and gene therapy.

Homologously recombinant cells of the present invention are useful in a number of applications in humans and animals. In one embodiment, the cells can be implanted into a human or an animal for protein delivery in the human or animal. For example, *TPO*, *DNase I*, or  $\beta$ -interferon can be delivered systemically or locally in humans for therapeutic benefit in the treatment of disease (*TPO* for thrombocytopenia, *DNase I* for CF, or  $\beta$ -interferon for the treatment of MS). In addition, homologously recombinant non-human cells producing *TPO*, *DNase I*, or  $\beta$ -interferon of non-human origin may be produced, and human or non-human

cells expressing TPO, DNase I, or  $\beta$ -interferon may be enclosed within barrier devices and implanted into humans or animals for use in a therapy.

#### Brief Description of the Drawings

5           Figure 1 is a schematic diagram of a strategy for transcriptionally activating the TPO gene by the creation of a novel transcription unit; thick lines: targeting sequences; thin lines: introns and 5' upstream region; cross-hatched box, regulatory sequence; stippled boxes: 10 noncoding exon sequences; black boxes: coding exon sequences; open boxes: splice sites. The splice-donor site (SD) of the exogenous exon in the targeting construct and the splice-acceptor site (SA) flanking TPO exon 2 which is involved in splicing to the exogenous exon are indicated.

15           Figure 2 is a schematic diagram of a strategy for transcriptionally activating the TPO gene by the creation of a novel transcription unit; thick lines: targeting sequences; thin lines: intron 1 and 5' upstream region; cross-hatched box: regulatory sequence; stippled boxes: 20 noncoding exon sequences; black boxes: coding exon sequences; open boxes, splice sites. The splice-donor site (SD) of the exogenous exon in the targeting construct and the splice-acceptor site (SA) flanking TPO exon 3 which is involved in splicing to the exogenous exon are indicated.

25           Figure 3 presents the 6,943 bp genomic XbaI fragment encompassing the 5' flanking region and exons 1, 2, and 3 of the human thrombopoietin (TPO) gene. The XbaI fragment is depicted by the solid line, while exons 1, 2, and 3 are represented by the solid boxes. The nucleotide positions of 30 the ApaI, BamHI, HindIII, EcoRI, NotI, SfiI and XbaI recognition sequences are indicated. Nucleotides are numbered starting at the hTPO ATG initiation codon.

Figures 4A-4D present the nucleotide sequence of 4,488 bp of genomic DNA (SEQ ID NO: 3) from the human *TPO* locus lying 5' to the known cDNA sequence (de Sauvage et al., op. cit.). Nucleotide numbers are noted at the beginning of each line. Numbering is based on the ATG initiation codon at position 1 (see Figures 5A-5B). Ambiguities in the nucleotide sequence are represented using the following code: R = A or G (purine); H = A, C, or T; V = A, C, or G; N\_ = A, C, G, or T; K = G or T; S = G or C; W = A or T. The recognition sites for *ApaI*, *BamHI*, *HindIII*, *NotI*, *SfiI* and *XbaI* and their corresponding nucleotide positions are indicated above the sequence.

Figures 5A-5B present the nucleotide sequence of 2,455\_bp of genomic DNA (SEQ ID NO: 4) from the human *TPO* locus extending downstream from the position of the 5' end of the known cDNA sequence (de Sauvage et al., op. cit.). Nucleotide numbers are noted at the beginning of each line. Numbering is based on the ATG initiation codon at position\_1. Shown are exon 1, intron 1, exon 2, intron 2, exon 3, and a portion of intron 3. Exons 1, 2, and 3 are underlined, and the coding portions of exons 2 and 3 are noted as underlined triplets. The intron-exon boundaries are deduced from the published cDNA sequence (de Sauvage et al., op. cit.). The recognition sites for *ApaI*, *EcoRI*, and *XbaI* and their corresponding nucleotide positions are indicated above the sequence.

Figure 6 is a schematic diagram of the strategy for activating the human *TPO* gene using targeting construct pTPO1 as described in Example 2. The positions of the *dhfr* and *neo* markers, the exogenous CMV promoter and *TPO* exons 1-3 are indicated. Thick lines: targeting sequences; thin lines: introns and 5' upstream region; cross-hatched box: CMV promoter; stippled boxes: noncoding exon sequences;

black boxes: coding exon sequences; open boxes, splice sites. The splice-donor site (SD) of the exogenous exon in the targeting construct and the splice-acceptor site (SA) flanking *TPO* exon 3 which is involved in splicing to the exogenous exon are indicated. Recognition sites for *Bam*HI (B), *Not*I (N), *Cla*I (C), *Xho*I (X), and *Xba*I which are relevant to the construction of the targeting construct are marked.

Figure 7 is a schematic diagram of the strategy for activating the human *TPO* gene using targeting construct pTPO2 as described in Example 2. The positions of the *dhfr* and neo markers, the exogenous CMV promoter and *TPO* exons 1-3 are indicated. Thick lines: targeting sequences; thin lines: introns and 5' upstream region; cross-hatched box: CMV promoter; heavily stippled boxes: noncoding exons from the CMV IE gene; lightly stippled boxes: noncoding exon sequences of *TPO* exons 1 and 2; black boxes: coding exon sequences of *TPO* exons 2 and 3; open boxes: splice sites. The splice-donor (SD) and splice-acceptor (SA) sites flanking the noncoding exons in the targeting construct and the splice-acceptor site (SA) flanking *TPO* exon 2 which is involved in splicing to the unpaired splice-donor site of the 3' exogenous exon are indicated. Recognition sites for *Bam*HI (B), *Hind*III (H), *Not*I (N), *Cla*I (C), *Sal*I (S), *Eco*RI (R), and *Xba*I which are relevant to the construction of the targeting construct are marked.

Figure 8 is a schematic diagram of the strategy for activating the human *TPO* gene using targeting construct pTPO3 as described in Example 2. The positions of the *dhfr* and neo markers, the exogenous CMV promoter and *TPO* exons 1-3 are indicated. Thick lines: targeting sequences; thin lines: introns and 5' upstream region; cross-hatched box: CMV promoter; stippled boxes: noncoding exon sequences of



TPO exons 1 and 2; black boxes: coding exon sequences (the coding exon corresponding to hGH exon 1 in the targeting construct and in the novel transcription unit is marked); open boxes: splice sites. The splice-donor site (SD) of the exogenous exon in the targeting construct and the splice-acceptor site (SA) flanking TPO exon 3 which is involved in splicing to the exogenous exon are indicated. Recognition sites for *Bam*HI (B), *Hind*III (H), *Cla*I (C), *Xho*I (X), *Eco*RI (R), and *Xba*I which are relevant to the construction of the targeting construct are marked.

Figure 9 is a diagrammatic representation of the approximately 8 kb *Hinc*II fragment encompassing the 5' flanking region, exons 1 and 2, and the sequences downstream of exon 2 of the human *DNase I* gene. The *Hinc*II fragment is depicted by the solid line, while exons 1 and 2 are represented by solid rectangular boxes. The nucleotide positions of the *Apa*I, *Bam*HI, *Hinc*II, *Esp*I, *Sph*I and *Sma*I recognition sequences are indicated. Nucleotides are numbered starting at the AUG initiation codon. The nucleotide positions which reside upstream of exon 2 are based on the DNA sequence presented in Figures 10 and 11.

Figures 10A-10D present the nucleotide sequence encompassing 4,042 bp of DNA (SEQ ID NO: 17) from the human *DNase I* locus lying 5' to the known cDNA sequence (Shak, S. et al. op. cit.). Nucleotides numbers are noted at the beginning of each line. Numbering is based on the ATG initiation codon at position 1 (see Figure 11). The recognition sites, and the corresponding nucleotide positions for *Apa*I, *Bam*HI, *Hinc*II, *Esp*I, and *Sph*I are indicated above the sequence.

Figure 11 presents the nucleotide sequence of 810 bp of DNA (SEQ ID NO: 18) from the human *DNase I* locus extending downstream from the position of the 5' end of the known cDNA



sequence (Shak, S. et al. op. cit.). Shown are exon 1, intron 1, and a portion of exon 2. Exon 1 and 2 sequences are underlined and the coding sequences are noted as underlined triplets. The positions of the putative CAP site and the AUG initiation codon are indicated. The intron-exon boundaries are deduced from the published cDNA sequence (Shak S. et al., op. cit.).

Figure 12 shows a strategy for activation of the human *DNase I* gene by homologous recombination. The targeting fragment is a 4633 bp *Bam*HI fragment from p*DNase*I which contains; 283 bp of 5' targeting sequence from position -1162 (*Bam*HI site) to -860 (*Apa*I site), an amplifiable *dhfr* expression unit, *neo* gene, CMV IE promoter, a CAP site, a non-codon exon, an unpaired splice-donor site and 363 bp of 3' targeting sequence from position -860 (*Esp*I site) to -468 (*Bam*HI site). The *dhfr* expression unit and the *neo* gene are depicted by open arrows, the orientation of the arrows represent the direction of transcription. The positions of the CMV promoter, TATA box, CAP site and splice donor sequence (SD) are indicated. Activation of the *DNase I* gene is achieved by integration of the targeting fragment into the genome of the recipient cells by homologous recombination. The targeted gene product is depicted in the lower panel of the figure. The mRNA precursor which includes a non-coding 5' exon, a chimeric intron and exon 2 of the *DNase* gene, is represented by the thin arrow.

Figure 13 is a diagrammatic representation of 9,939 bp encompassing the 5' flanking region, coding sequence and the 3' untranslated region of the human  $\beta$ -interferon gene. The 5' and 3' flanking regions are depicted by the solid line and the transcribed region is represented by the solid box. The nucleotide positions of the *Bal*I, *Bgl*III, *Eco*RI and *Pvu*II recognition sequences are indicated. Nucleotides are

numbered starting at the  $\beta$ -interferon ATG translational initiation codon (see Figure 15).

Figures 14A-14G present the nucleotide sequence of 8,355 bp of DNA (SEQ ID NO: 23) from the human  $\beta$ -interferon locus lying 5' to the known sequence (GenBank HUMIFNB1F). Nucleotide numbers are noted at the beginning of each line. Numbering is based on the ATG initiation codon at position 1 (see Figures 15). The recognition sites for *Bgl*III, *Eco*RI and *Pvu*II and their corresponding nucleotide positions are indicated above the sequence.

Figures 15A-15B present the nucleotide sequence of 1,584 bp of DNA (SEQ ID NO: 24) from the human  $\beta$ -interferon locus extending downstream from the 5' end of the known sequence (GenBank HUMIFNB1F). Nucleotide numbers are noted at the beginning of each line. Numbering is based on the ATG initiation codon at position 1. The transcribed region is underlined and the coding sequences are noted as underlined triplets. The position of the CAP site and AUG initiation codon are indicated. The recognition sites for *Bal*I, *Bgl*III and *Pvu*II and their corresponding nucleotide positions are indicated above the sequence.

Figure 16 depicts the strategy for activation of the human  $\beta$ -interferon gene by homologous recombination using targeting construct pIFNb-1 as described in Example 7. The positions of the TATA box, CAP site, *dhfr* and *neo* markers, the exogenous CMV promoter, and the  $\beta$ -interferon 5' flanking region and coding sequence are indicated. Thick lines: targeting sequences; thin lines: intron,  $\beta$ -interferon 5' and 3' non-coding sequences; solid box: CMV promoter; shaded box: endogenous  $\beta$ -interferon transcribed region; cross-hatched box: non-coding CMV exon 1 and the chimeric exon 2. The splice-donor site (SD) of the exogenous exon and the splice-acceptor site (SA) flanking the chimeric exon 2

are indicated. Recognition sites for *Bam*HI, *Eco*RI, *Hinc*II, *Nde*I and *Pvu*II which are relevant to the construction of the targeting construct are marked.

#### Detailed Description of the Invention

5 The present invention as set forth above, relates to a method of expressing TPO, DNase I, or  $\beta$ -interferon in human cells by activation of the endogenous *TPO*, *DNase I*, or  $\beta$ -*interferon* genes. In the present invention, homologous recombination is used to insert a regulatory region, an  
10 exon, and a splice-donor site upstream of endogenous exons coding for TPO, DNase I, or  $\beta$ -interferon, generating novel transcription units which are active in the homologously recombinant cell produced. The present invention further relates to homologously recombinant cells produced by the  
15 present method and to uses of the homologously recombinant cells. In a related embodiment, an activated *TPO*, *DNase I*, or  $\beta$ -*interferon* gene is amplified subsequent to activation, thus allowing enhanced expression of the activated gene.

The invention is based upon the discovery that the  
20 regulation or activity of endogenous genes of interest in a cell can be altered by creating a novel gene, in which the transcription product of the gene combines exogenous and endogenous exons and is under the control of an exogenous promoter. The method is practiced by inserting into a  
25 cell's genome, at a preselected site, through homologous recombination, DNA constructs comprising: (a) one or more targeting sequences; (b) a regulatory sequence; (c) an exon and (d) an unpaired splice-donor site, wherein the targeting sequence or sequences are derived from chromosomal DNA  
30 within and/or upstream of a desired endogenous gene and directs the integration of elements (a) - (d) such that the elements (b) - (d) are operatively linked to the endogenous

gene. In another embodiment, the DNA constructs comprise:  
(a) one or more targeting sequences, (b) a regulatory  
sequence, (c) an exon, (d) a splice-donor site, (e) an  
intron, and (f) a splice-acceptor site, wherein the  
5 targeting sequence or sequences are derived from chromosomal  
DNA within and/or upstream of a desired endogenous gene and  
directs the integration of elements (a) - (f) such that the  
elements of (b) - (f) are operatively linked to the first  
exon of the endogenous gene.

10 The present invention relates particularly to novel DNA  
sequences that can be used in the construction of targeting  
constructs. Non-coding genomic DNA sequences within and  
upstream of the transcribed regions of the *TPO* and *DNase I*  
genes, and upstream of the transcribed region of the  
15  $\beta$ -interferon gene, were cloned and are described for the  
first time. These sequences or DNA fragments comprising  
these sequences may be used as targeting sequences in DNA  
constructs useful for gene activation by homologous  
recombination. Typically, a targeting sequence is at least  
20 about 20 base pairs in length. The size of the sequence is  
chosen to be a size which selectively promotes homologous  
recombination with desired genomic DNA sequences.

Analysis of the genomic DNA sequences and comparison to  
the known cDNA sequences revealed features essential for the  
25 construction of targeting constructs. For example, for the  
first time, it is shown that the first exon of the human *TPO*  
gene is entirely non-coding, and that translation initiates  
within the second exon of the endogenous gene. This  
information was important to the design of the gene  
30 activation constructs described herein, in which splicing of  
an exogenous exon to the endogenous second exon requires  
that the exogenous exon be non-coding, or in which splicing  
of an exogenous coding exon requires that targeting be

performed such that the exogenous coding exon is inserted in a position so that it can be spliced to the endogenous third exon of the *TPO* gene. Furthermore, the cloning of approximately 6.3 kb of DNA sequence from upstream of the human *TPO* gene provided targeting sequences useful for the development of gene activation constructs. Figure 4 shows approximately 4.5 kb of novel DNA sequence from the human *TPO* locus lying 5' of the known cDNA sequence (de Sauvage, F. J. et al., op. cit.). Figure 5 shows approximately 2.5 kb of DNA sequence from the human *TPO* locus extending in the 3' direction from the 5' boundary of the known cDNA sequence. Intron sequences (positions -1815 to -145, positions 14 to 245, and positions 374 to 570) of Figure 5 are novel. DNA constructs comprising the novel sequences of Figures 4 and 5, or fragments derived from these sequences, are useful for homologous recombination as taught herein.

Similarly, for the first time it is shown that the first exon of the human *DNase I* gene is entirely non-coding. This information was important to the design of the targeting constructs described herein. Example 5, for example, describes a targeting construct which includes two non-coding exons separated by an intron, and which is inserted upstream of *DNase I* exon 1. This configuration allows promoter position to be optimized by varying the length of either the exogenous intron or the intron present between the exogenous exon and the endogenous second exon of the *DNase I* gene, while ensuring that the primary transcript will be spliced appropriately and that translation initiates at the correct position for synthesis of functional *DNase I*. Furthermore, the cloning of approximately 4.5 kb of DNA sequence from upstream of the human *DNase I* gene provided targeting sequences useful for the development of gene activation constructs. Figure 10 shows approximately 4 kb

of novel DNA sequence from the human *DNase I* locus lying 5' of the known cDNA sequence (Shak, S. et al. op. cit.).

Figure 11 shows approximately 0.8 kb of DNA sequence from the human *DNase I* locus extending in the 3' direction from the 5' boundary of the known cDNA sequence. Intron sequences (positions -328 to -2) of Figure 11 are novel. DNA constructs comprising the novel sequences of Figures 10 and 11, or fragments derived from these sequences, are useful for homologous recombination as described herein.

Finally, the analysis of the upstream region of the  $\beta$ -interferon gene (a gene which is known to lack introns) was cloned and sequenced and a detailed restriction map was produced. Previously, only 357 bp of DNA upstream of the translation initiation codon was characterized (see Genbank entry HUMIFNB1F). The cloning and sequence analysis provided approximately 9.6 kb of genomic DNA upstream of the gene for the design and construction of a targeting construct (Example 7). Figure 14 shows approximately 8.4 kb of novel DNA sequence from the  $\beta$ -interferon locus lying 5' of the known sequences (Genbank entry HUMIFNB1F). DNA constructs comprising the novel sequences of Figure 14, or fragments derived from these sequences, are useful for homologous recombination as taught herein.

The following defines the DNA constructs of the present invention, the elements comprising the DNA constructs of the present invention (Section A), methods in which the DNA constructs are used to produce homologously recombinant cells (Section B), the structure of the targeted gene and the resulting product (Section C), the homologously recombinant cells produced (Section D), uses of these cells (Sections E and F), and the advantages of the constructs and methods described herein (Section G).

## A. The DNA Construct

The DNA constructs of the present invention include at least the following components: a targeting sequence; a regulatory sequence; an exon and a splice-donor site. In the construct, the exon is 3' of the regulatory sequence and the splice-donor site is 3' of the exon. In addition, there can be multiple exons and/or introns preceding (5' to) the exon flanked by the splice-donor site. Taken as a group, the exons, introns, and splice-sites are referred to as the "structural elements" of the construct, so-called because they are important in defining the structure of the novel gene produced by homologous recombination between genomic DNA and DNA of the targeting construct. As described herein, there frequently are additional construct components, such as a selectable and/or amplifiable markers.

The DNA in the construct is referred to as exogenous DNA, defined herein as DNA which is introduced into a cell by the methods described herein, such as with the DNA constructs of the present invention. Exogenous DNA can contain sequences identical to or different from the endogenous DNA. The term endogenous DNA is defined herein as DNA present in the cell as obtained.

The DNA of the construct can be obtained from sources in which it occurs in nature or can be produced, using genetic engineering techniques or synthetic processes.

### **1. The Targeting Sequence**

The targeting sequence or sequences are DNA sequences which permit homologous recombination into the genome of the selected cell containing the gene of interest. Targeting sequences are, generally, DNA sequences which are homologous to (i.e., identical or sufficiently similar to) DNA sequences present in the genome of the cells as obtained (e.g., coding or noncoding DNA, located upstream of the



transcriptional start site, within the transcribed region encompassing the gene, or downstream of the transcriptional stop site of the gene, or sequences present in the genome through a previous modification), such that the targeting  
5 sequence and cellular DNA can undergo homologous

recombination. In general, two sequences are described as homologous if a DNA strand of one sequence is capable of hybridizing to a DNA strand of the other sequence under conditions standardly used for the detection of sequence  
10 similarity (see, for example, Ausubel et al., *Current Protocols in Molecular Biology*, Wiley, New York, NY.

(1987)). The targeting sequence or sequences used are selected with reference to the site into which the DNA in the DNA construct is to be inserted and may be derived from  
15 either genomic or cDNA sequences. Typically, a targeting sequence is at least about 20 base pairs in length. The size of the sequence is chosen to be a size which selectively promotes homologous recombination with desired genomic DNA sequences.

20 One or more targeting sequences can be employed. For example, a circular plasmid or DNA fragment preferably employs a single targeting sequence. A linear plasmid or DNA fragment preferably employs two targeting sequences with exogenous DNA to be inserted into genome positioned between  
25 the two targeting sequences. The targeting sequence or sequences can be within an endogenous gene (e.g., within the sequences of an exon and/or intron), within the endogenous promoter sequences, or upstream of the endogenous promoter sequences. The targeting sequence or sequences can include  
30 those regions of a gene presently known or sequenced and/or regions further upstream which are structurally uncharacterized but can be mapped using restriction enzymes and cloning approaches available to one skilled in the art.



## 2. The Regulatory Sequence

The regulatory sequence of the DNA construct can be comprised of one or more of a variety of elements, including: promoters (such as a constitutive or inducible promoters), enhancers, scaffold-attachment regions or matrix attachment regions, (McKnight, R.A. et al., *Proc. Natl. Acad. Sci. USA* 89:6943-6947 (1992); Phi-Van, L. and Strätling, W.H. *EMBO J.* 7:655-664 (1988)) negative regulatory elements, locus control region, (Pondel, M.D. et al., *Nucl. Acids Res.* 20:237-243 (1992); Li, Q. and Stamatoyannopoulos, G. *Blood* 84:1399-1401 (1994)) transcription factor binding sites, or combinations of said sequences.

## 3. Structural Elements of the DNA Construct

### a. Exons and Introns

An exon is defined herein as a DNA sequence which is copied into RNA and is present in a mature mRNA molecule. An intron is defined as a sequence of one or more nucleotides lying between two exons and which is removed, by splicing, from a precursor RNA molecule in the formation of an mRNA molecule.

The DNA constructs of the present invention contain one or more exons. The exons can, optionally, contain DNA which encodes one or more amino acids and/or partially encodes an amino acid (*i.e.*, one or two bases of a codon). Where the exogenous exon or exons encode one or more amino acids and/or a portion of an amino acid, the DNA construct is designed such that, upon transcription and splicing, the reading frame is in-frame with the second or subsequent exon of the endogenous gene's coding region. As used herein, in-frame means that the encoding sequences of, for example, a first exon and a second exon when fused, join together

nucleotides in a manner that does not change the appropriate reading frame of the portion of the mRNA derived from the second exon.

In the case of activating the *TPO* and *DNase I* genes, the exogenous exon can, preferably, be derived from any gene in which the exon includes a CAP site and non-coding sequences. Examples would include the first exon of the CMV immediate-early gene and follicle stimulating hormone (*FSH*) gene. In the case of  $\beta$ -interferon, whose gene contains no natural introns, there are preferably two exogenous non-coding exons, separated by an intron, in the targeting construct.

#### **b. Splice-Sites**

Introns contained within the mRNA of eukaryotic cells are removed through the recognition of signals termed splice-donor and splice-acceptor sites. A splice-donor site is a sequence which directs the splicing of one exon to another exon. Typically, the first exon lies 5' of the second exon, and the splice-donor site overlapping and flanking the first exon on its 3' side recognizes a splice-acceptor site flanking the second exon on the 5' side of the second exon. Splice-donor sites have a characteristic consensus sequence represented as:

(A/C)AGGURAGU (where R denotes a purine nucleotide) with the GU in the fourth and fifth positions being required (Jackson, I.J., *Nucleic Acids Research* 19: 3715-3798 (1991)). The first three bases of the splice-donor consensus site are the last three bases of the exon. Splice-donor sites are functionally defined by their ability to effect the appropriate reaction within the mRNA splicing pathway.

An unpaired splice-donor site is defined herein as a splice-donor site which is present in a targeting construct

and is not accompanied in the targeting construct by a splice-acceptor site positioned 3' to the unpaired splice-donor site. Upon homologous recombination between the targeting sequences and genomic DNA, the unpaired splice-donor site results in splicing to an endogenous splice-acceptor site.

A splice-acceptor site is a sequence which, like a splice-donor site, directs the splicing of one exon to another exon. Acting in conjunction with a splice-donor site, the splicing apparatus uses a splice-acceptor site to effect the removal of an intron. Splice-acceptor sites have a characteristic sequence represented as: YYYYYYYYYNYAG, where Y denotes any pyrimidine and N denotes any nucleotide (Jackson, I.J., *Nucleic Acids Research* 19:3715-3798 (1991)).

**c. Marker Genes for Selection and Amplification**

The identification of the targeting event can be facilitated by the use of one or more selectable marker genes typically contained within the targeting DNA construct. The use of both positively and negatively selectable markers for identifying targeted events is described in related pending applications U.S.S.N. 08/243,391, U.S.S.N. 07/985,586, U.S.S.N. 07/789,188, PCT/US93/11704, and PCT/US92/09627.

Homologously recombinant cells containing multiple copies of the novel transcription units produced by the present invention may be isolated by including within the targeting DNA construct an amplifiable marker gene which has the property that cells containing multiple copies of the selectable marker gene can be selected for by culturing the cells in the presence of an appropriate selectable agent. The novel transcription unit will be amplified in tandem with the amplified selectable marker gene, allowing the production of very high levels of the desired protein.

Amplifiable marker genes and their use are described in applications U.S.S.N. 08/243,391, U.S.S.N. 07/985,586, and PCT/US93/11704.

5 In one embodiment the positively selectable marker *neo* is used (derived from the bacterial *neomycin phosphotransferase* gene) is used to select for cells which have stably incorporated the DNA of the targeting construct, and the mouse *dhfr* (*dihydrofolate reductase*) gene is used to subsequently amplify the novel transcription unit present in  
10 homologously recombinant cells.

**d. Additional Elements of the Targeting Construct**

As taught herein, gene targeting can be used to insert a regulatory sequence within an endogenous gene (e.g., within the sequences of an exon and/or intron), within the  
15 endogenous promoter sequences, or upstream of the endogenous promoter sequences, with said genes corresponding to the endogenous cellular *TPO*,  $\beta$ -interferon, or *DNase I* gene. Alternatively or additionally, the targeting constructs may be designed to include sequences which affect the structure or stability of the *TPO*,  $\beta$ -interferon, or *DNase I* protein or  
20 corresponding RNA molecule. For example, RNA stability elements, splice sites, and/or leader sequences of RNA molecules can be modified to improve or alter the function, stability, and/or translatability of an RNA molecule. Protein sequences may also be altered, such as signal  
25 sequences, active sites, and/or structural sequences for enhancing or modifying glycosylation, transport, secretion, or functional properties of a protein. According to this method, introduction of the exogenous DNA results in the  
30 alteration of the structural or functional properties of the expressed proteins or RNA molecules.

In one embodiment the method can be used to create novel transcription units encoding fusion proteins in which

structural, enzymatic, or ligand or receptor binding protein domains of another protein are fused to TPO, DNase I, or  $\beta$ -interferon. In these cases the exogenous coding DNA contains an ATG translation initiation codon in-frame with the coding sequences of the endogenous *TPO*, *DNase I*, or  *$\beta$ -interferon* gene. For example, the exogenous DNA can encode a sequence which can anchor TPO or DNase I to a membrane, a portion of a signal peptide designed to improve cellular secretion, leader sequences, enzymatic regions, transmembrane domain regions, co-factor binding regions, or other functional regions.

The DNA construct can also include a bacterial origin of replication and bacterial antibiotic resistance markers or other selectable markers, which allow for large-scale plasmid propagation in bacteria or any other suitable cloning/host system.

#### B. Transfection and Homologous Recombination

According to the present method, the construct is introduced into the cell, such as a primary, secondary, or immortalized cell, as a single DNA construct, or as separate DNA sequences which become incorporated into the chromosomal or nuclear DNA of a transfected cell.

The targeting DNA construct can be introduced into cells on a single DNA construct or on separate constructs. The total length of the DNA construct will vary according to the number of components and the length of each and the construct will generally be at least about 200 nucleotides. Further, the DNA can be introduced as linear, double-stranded (with or without single-stranded regions at one or both ends), single-stranded, or circular DNA.

Any of the construct types of the disclosed invention is then introduced into the cell to obtain a transfected

cell. The transfected cell is maintained under conditions which permit homologous recombination, as is known in the art (reviewed in Capecchi, M.R., *Science* 244:1288-1292 (1989)). When the homologously recombinant cell is maintained under conditions sufficient for transcription of the DNA, the regulatory region introduced by the targeting construct, as in the case of a promoter, will activate expression of the novel transcription unit produced by homologous recombination.

The DNA constructs may be introduced into cells by a variety of physical or chemical methods, including electroporation, microinjection, microprojectile bombardment, calcium phosphate precipitation, and liposome-, polybrene-, or DEAE dextran-mediated transfection.

#### C. The Targeted Gene and Resulting Product

The targeting DNA construct, when introduced by homologous recombination or targeting into cells containing the *TPO*,  $\beta$ -interferon, or *DNase I* gene, produces a novel transcription unit which results in the expression of *TPO*,  $\beta$ -interferon, or *DNase I*.

At the targeted site in the genome, the exogenous regulatory sequence is operatively linked to a CAP site, which initiates transcription. Operatively linked is defined as a configuration in which the exogenous regulatory sequence, exon, splice-donor site and, optionally, an intron sequence and splice-acceptor site, are appropriately targeted at a position relative to the endogenous gene such that the regulatory element directs the production of a primary RNA transcript which initiates at a CAP site and includes sequences corresponding to the exogenous exon or exons and endogenous exons the *TPO*, *DNase I*, or  $\beta$ -interferon gene. In an operatively linked configuration the

splice-donor site of the targeting construct directs a splicing event between an exogenous exon and the splice-acceptor site of an endogenous exon, such that a desired protein can be produced from the fully spliced mature transcript. In one embodiment, the splice-acceptor site is endogenous, such that the splicing event is directed to an endogenous exon of the *TPO* or *DNase I* gene. In another embodiment an intron and a splice-acceptor site are included in the targeting construct used to activate the  $\beta$ -interferon gene, and a splicing event removes the intron introduced by the targeting construct.

#### D. The Homologously Recombinant Cells

The targeting event results in the insertion of the regulatory and structural sequences of the targeting construct into a cell's genome, creating a novel transcriptional unit under the control of the exogenous regulatory sequences.

Homologous recombination between the genomic DNA and the introduced DNA results in a homologously recombinant cell, which may be a primary, secondary, or immortalized human or other mammalian cell in which sequences which alter the expression of an endogenous gene are operatively linked to the endogenous *TPO*, *DNase I*, or  $\beta$ -interferon gene. Particularly, the invention includes a homologously recombinant cell comprising exogenous regulatory sequences and an exon, flanked by a splice-donor site, which are introduced at a predetermined site by a targeting DNA construct, and are operatively linked to the coding region of the endogenous gene. Optionally, there may be multiple exogenous exons (coding or non-coding) and introns operatively linked to any exon of the endogenous gene. The resulting homologously recombinant cells are cultured under



conditions which select for amplification, if appropriate, of the DNA encoding the amplifiable marker and the novel transcriptional unit. With or without amplification, cells produced by this method can be cultured under conditions, as  
5 are known in the art, suitable for the expression of TPO,  $\beta$ -interferon, or DNase I.

The targeting constructs and methods of the present invention may be used with, for example, primary or secondary cell strains (which exhibit a finite number of  
10 mean population doublings in culture and are not immortalized) and immortalized cell lines (which exhibit an apparently unlimited lifespan in culture). Primary and secondary cells include, for example, fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial  
15 cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells and precursors of these somatic cell types. Where the homologously recombinant cells are to be used in gene  
20 therapy, primary cells are preferably obtained from the individual to whom the resulting homologously recombinant cells are administered. However, primary cells can be obtained from a donor (other than the recipient) of the same species. Examples of immortalized human cell lines which  
25 may be used with the DNA constructs and methods of the present invention include, but are not limited to, HT1080 cells (ATCC CCL 121), HeLa cells and derivatives of HeLa cells (ATCC CCL 2, 2.1 and 2.2), MCF-7 breast cancer cells (ATCC BTH 22), K-562 leukemia cells (ATCC CCL 243), KB  
30 carcinoma cells (ATCC CCL 17), 2780AD ovarian carcinoma cells (Van der Blick, A.M. et al., *Cancer Res*, 48:5927-5932 (1988), Raji cells (ATCC CCL 86), WiDr colon adenocarcinoma cells (ATCC CCL 218), SW620 colon adenocarcinoma cells (ATCC



CCL 227), Jurkat cells (ATCC TIB 152), Namalwa cells (ATCC CRL 1432), HL-60 cells (ATCC CCL 240), Daudi cells (ATCC CCL 213), RPMI 8226 cells (ATCC CCL 155), U-937 cells (ATCC CRL 1593), Bowes Melanoma cells (ATCC CRL 9607), WI-38VA13  
5 subline 2R4 cells (ATCC CLL 75.1), and MOLT-4 cells (ATCC CRL 1582), as well as heterohybridoma cells produced by fusion of human cells and cells of another species. Secondary human fibroblast strains, such as WI-38 (ATCC CCL 75) and MRC-5 (ATCC CCL 171) may be used. Further  
10 discussion of the types of cells that may be used in practicing the methods of the present invention is presented in applications U.S.S.N. 08/243,391, U.S.S.N. 07/985,586, U.S.S.N. 07/789,188, U.S.S.N. 07/911,533, U.S.S.N. 07/787,840, PCT/US93/11704, and PCT/US92/09627.

15 E. In Vivo Protein Production

Homologously recombinant cells of the present invention in which the expression properties of the endogenous *TPO*,  $\beta$ -interferon, or *DNase I* gene are altered are useful in gene therapy, as populations of homologously recombinant cell  
20 lines, as populations of homologously recombinant primary or secondary cells, homologously recombinant clonal cell strains or lines, homologously recombinant heterogenous cell strains or lines, and as cell mixtures in which at least one representative cell of one of the preceding categories of  
25 homologously recombinant cells is present. Homologously recombinant primary cells, clonal cell strains or heterogenous cell strains are administered to an individual in whom the abnormal or undesirable condition is to be treated or prevented, in sufficient quantity and by an  
30 appropriate route, to express or make available the desired product at physiologically relevant levels. A physiologically relevant level is one which either

approximates the level at which the product is normally produced in the body or results in improvement of the abnormal or undesirable condition. Methods for gene therapy in which homologously recombinant cells are introduced into an individual for the purpose of in vivo protein production are described in pending applications U.S.S.N. 08/243,391, U.S.S.N. 07/985,586, U.S.S.N. 07/789,188, U.S.S.N. 07/911,533, U.S.S.N., PCT/US93/11704, and PCT/US92/09627.

In one embodiment, the invention relates to a method of providing TPO to a mammal introducing homologously recombinant cells into the mammal in sufficient number to produce an effective amount of TPO in the mammal.

In another embodiment homologously recombinant cells expressing DNase I can be administered to the trachea and lungs of a cystic fibrosis patient, for the purpose of in vivo secretion of DNase I for the relief of respiratory distress.

In a third embodiment, homologously recombinant cells expressing  $\beta$ -interferon may be implanted into a patient suffering from multiple sclerosis, for the purpose of in vivo secretion of  $\beta$ -interferon to diminish exacerbations associated with the disease.

#### F. In Vitro Protein Production

Homologously recombinant cells produced according to this invention can also be used for in vitro production of TPO,  $\beta$ -interferon, or DNase I. The cells are maintained under conditions, as are known in the art, which result in expression of the protein. Proteins expressed using the methods described may be purified from cell lysates or cell supernatants. Proteins made according to this method can be prepared as a pharmaceutically-useful formulation and delivered to a human or non-human animal by conventional

pharmaceutical routes as is known in the art (e.g., oral, intravenous, intramuscular, intranasal, intratracheal or subcutaneous). As described herein, the homologously recombinant cells can be immortalized, primary, or secondary human cells. The use of cells from other species may be desirable in cases where the non-human cells are advantageous for protein production purposes where the non-human TPO, DNase I, or  $\beta$ -interferon produced is useful therapeutically.

#### 10 G. Advantages

The methodologies, DNA constructs, cells, and resulting proteins of the invention herein possess versatility and many other advantages over processes currently employed within the art in gene targeting. The ability to activate expression of an endogenous *TPO*,  *$\beta$ -interferon*, or *DNase I* gene by positioning an exogenous regulatory sequence and other structural sequences at various positions ranging from directly fused to portions of the normal gene's coding region to 30 kilobase pairs or further upstream of the transcribed region of an endogenous gene, or within an intron of an endogenous gene, is advantageous for gene expression in cells. For example, it can be employed to position the regulatory element upstream or downstream of regions that normally silence or negatively regulate a gene. The positioning of a regulatory element upstream or downstream of such a region can override such dominant negative effects that normally inhibit transcription. In addition, regions of DNA that normally inhibit transcription or have an otherwise detrimental effect on the expression of a gene may be deleted using the targeting constructs, described herein. The present invention also allows proteins to be expressed in the context of their normal

intron sequences, which have been shown to be important factors in the expression of genes in mammalian cells (cf. Korb. M. et al. *Nucl. Acids Res.* 21: 5901-5908 (1993)).

Additionally, since promoter function is known to  
5 depend strongly on the local environment, a wide range of positions may be explored in order to find those local environments optimal for function. However, since, ATG start codons are found frequently within mammalian DNA (approximately one occurrence per 48 base pairs as  
10 calculated from nearest-neighbor dinucleotide frequencies in human DNA), transcription cannot simply initiate at any position upstream of a gene and produce a transcript containing a long leader sequence preceding the correct ATG start codon, since the frequent occurrence of ATG codons in  
15 such a leader sequence will prevent translation of the correct gene product and render the message useless. Thus, the incorporation of an exogenous exon, a splice-donor site, and, optionally, an intron and a splice-acceptor site into targeting constructs comprising a regulatory region allows  
20 gene expression to be optimized by identifying the optimal site for regulatory region function, without the limitation imposed by needing to avoid inappropriate ATG start codons in the mRNA produced. This provides significantly increased flexibility in the placement of the construct and makes it  
25 possible to activate a wider range of genes than is possible using other technologies. For example, U.S. Patent No. 5,272,071 and foreign patent applications WO 91/06666, WO 91/06667 and WO 90/11354 describe homologous recombination methods for inserting a regulatory sequence upstream of the  
30 coding region of an endogenous gene. In these methods, only a very small number of positions for promoter insertion are acceptable for expression, limited by the frequent occurrence of ATG start codons as described above.

The present invention provides further advantages over the methods available in the art. For example, the use of homologous recombination results in the production of cells in which the novel transcription unit is present in the same location in all cells in which homologous recombination has occurred. Thus, the novel transcription unit will function similarly in all homologously recombinant cells derived independently. This allows for the production of cells with highly predictable properties. In the case of in vitro protein production, it is desirable to develop cells in which the behavior (e.g. the expression and amplification properties) of the desired gene can be controlled and there is little variation when comparing individual cells which are being processed for large-scale production purposes. In the case of in vivo protein production or gene therapy, it is desirable to be able to develop cells in which the properties are predictable and uniform among individual patients. This allows for a high degree of precision in achieving appropriate levels of the desired protein in vivo, leading to controlled and reproducible methods for treating disease.

The DNA constructs described above are useful for operatively linking exogenous regulatory and structural elements to endogenous coding sequences in a way that precisely creates a novel transcriptional unit, provides flexibility in the relative positioning of exogenous regulatory elements and endogenous genes and, ultimately, enables a highly controlled system for and regulating expression of genes of therapeutic interest.

The subject invention will now be illustrated by the following examples, which are not intended to be limiting in any way.

## EXAMPLES

### EXAMPLE 1: Cloning of the TPO Gene and Identification of 5' Flanking Sequences

The human thrombopoietin gene was isolated from a human genomic DNA library. The library was prepared from male leukocyte DNA partially-digested with *Mbo*I and cloned into the bacteriophage vector lambda EMBL3 (Clontech, Palo Alto, CA; Cat. #HL1006d). For screening, a probe was isolated by PCR amplification of human genomic DNA using oligonucleotides 1.1 and 1.2.

Oligo 1.1 (TPO sense) (SEQ ID NO: 1)

5' AATTGCTCCT CGTGGTCATG CTTCT

Oligo 1.2 (TPO anti-sense) (SEQ ID NO: 2)

5' CTGTGAAGGA CATGGGAGTC A

These primers were designed using the known TPO mRNA sequence (de Sauvage, F. J. et al. *Nature* 369:533-538 (1994)). The amplified probe (probe A; 120 bp) was labeled with <sup>32</sup>P dCTP by the polymerase chain reaction and used to screen the genomic DNA library. Filters were hybridized for 6 hours at 68°C in 125 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 250 mM NaCl, 10% PEG 8000, 7% SDS, 1 mM EDTA. Filters were washed twice in 500 ml of 20 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 1 mM EDTA, 5% SDS, followed by 4 washes in 500 ml of 20 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 1 mM EDTA, 1% SDS. The wash buffers were pre-heated to 56°C and washing was done on a rotary shaker at room temperature for approximately 5 minutes per wash. The hybridizing signals were identified by autoradiography at -80°C with an intensifying screen. In one experiment,

approximately  $1.4 \times 10^6$  phage were screened and 7 positive signals were obtained. Phage plaques corresponding to positive signals were plaque purified. Following 2 rounds of plaque purification by low density screening using probe A, 4 of the phage, designated 5B, 25A, 25B and 28B, were retained for further analysis. Plaque purified phage were amplified and isolated by cesium chloride gradient ultracentrifugation (Yamamoto K.R. et al., *Virology* 40:734 (1970)) and DNA was isolated. Library screening, plaque purification of recombinant bacteriophage, and isolation bacteriophage DNA was performed using standard methods (Ausubel et al., *Current Protocols in Molecular Biology*, Wiley, New York, NY. (1987)).

An approximately 6.9 kb XbaI fragment comprising exon 1, intron 1, exon 2, intron 2, exon 3, and a portion of intron 3, as well as approximately 4.3 kb of nontranscribed DNA lying upstream of TPO exon 1 was identified by restriction enzyme and Southern hybridization analysis using probe A. This fragment was isolated from one genomic clone (28B) and subcloned into plasmid pBSISK<sup>+</sup> (Stratagene Inc., La Jolla, CA) for further analysis. The resultant clones, pBS(X)/5'Thromb.8 and pBS(X)/5'Thromb.2, harbor the 6.9 kb XbaI fragment in opposite orientations with respect to the plasmid backbone. Restriction enzyme mapping yielded the restriction enzyme map shown in Figure 3. The nucleotide sequence of the portion of this fragment lying upstream of the 5' end of the known cDNA sequence is shown in Figure 4 (SEQ ID NO: 3). The nucleotide sequence of the portion of the 6.9 kb XbaI fragment lying downstream of the 5' end of the known cDNA sequence is shown in Figure 5 (SEQ ID NO: 4). Comparison of the cloned genomic sequence presented here with the published cDNA sequence (de Sauvage, F. J. et al. *Nature* 369:533-538 (1994)) reveals



that the 5' end of the TPO gene consists of a non-coding exon (exon 1) of at least 107 bp, a second exon (exon 2) which is 158 bp, and a third exon (exon 3) which is 128 bp in length. The 13 base pairs at the 3' end of exon 2 code for the first four and a portion of the fifth amino acid of the TPO signal peptide. Exon 3 codes for the remainder of the 21 amino acid signal peptide and a portion of the mature TPO polypeptide. Exons 1 and 2 are separated by intron 1 (1671 bp), and exons 2 and 3 are separated by intron 2 (231 bp). There are two differences between the sequence reported in Figure 5 and the sequence published by de Sauvage et al.: nucleotides at positions -134 and -124 are reported as C residues by de Sauvage et al. and are shown as T residues in Figure 5. These residues are outside of the coding sequence for TPO and may be explained by sequence polymorphism or by errors in compilation of the published sequence. In any event, this minor difference does not impact the ability of the person of skill to practice the invention as described herein.

EXAMPLE 2: Construction of Targeting Plasmids for Activation and Amplification of the TPO Gene

The activation of the TPO gene can be accomplished by a number of strategies, as shown in Figures 6-8. In the strategy shown in Figure 6, a targeting fragment is introduced into the genome of recipient cells for insertion of a regulatory region, a non-coding exon, and a functional, unpaired splice-donor site upstream of the TPO coding region. Specifically, the targeting construct from which this fragment is derived (pRTPO1) is designed to include a first targeting sequence homologous to sequences upstream of the TPO gene, an amplifiable marker gene, a selectable marker gene, a regulatory region, a CAP site, a



non-coding exon, an unpaired splice-donor site, and a second targeting sequence corresponding to sequences downstream of the first targeting sequence but upstream of *TPO* exon 1. By this strategy, homologously recombinant cells produce an mRNA precursor which includes the non-coding exon introduced upstream of the *TPO* gene by homologous recombination, the second targeting sequence and any sequences between the second targeting sequence and exon 2 of the *TPO* gene, and the remaining exons, introns, and 3' untranslated regions of the *TPO* gene (Figure 6). Splicing of this message results in the fusion of the exogenous non-coding exon to exon 2 of the endogenous *TPO* gene which, when translated, will produce TPO. In this strategy the first and second targeting sequences are upstream of the normal target gene, but this is not required (see below). The size of the intron in the targeting construct and thus the position of the regulatory region relative to the coding region of the gene may be varied to optimize the function of the regulatory region.

Plasmid pRTPO1 is constructed as follows: Based on the restriction map of the *TPO* upstream region (Figure 3), a 3.5 kb *Bam*HI fragment can be isolated from subclone pBS(X)/5'Thromb.8 (Example 1). This fragment is ligated to *Bam*HI digested plasmid pBS (Stratagene, Inc., La Jolla, CA) and transformed into competent *E. coli* cells to generate pBS-TPO1. This fragment includes sequences lying upstream of *TPO* exon 1. Next, a 0.73 kb fragment was amplified from hGH expression construct pXGH308, which has the CMV immediate-early (IE) gene promoter region beginning at nucleotide 546 and ending at nucleotide 2105 of Genbank sequence HS5MIEP fused to the hGH sequences beginning at nucleotide 5225 and ending at nucleotide 7322 of Genbank sequence HUMGHCSA, using oligonucleotides 2.1 and 2.2.

(The source of the CMV IE gene is not critical, and other CMV IE promoter-based plasmids may be used, or wild-type CMV DNA may be used.) Oligo 2.1 (37 bp, SEQ ID NO: 5), hybridizes to the CMV IE promoter at -614 relative to the cap site (in Genbank sequence HEHCMVP1), and includes a NotI site followed by a partially overlapping XhoI site at its 5' end. Oligo 2.2 (36 bp, SEQ ID NO: 6), hybridizes to the CMV IE promoter at +131 relative to the cap site and includes the first 10 base pairs of the first intron of the CMV IE gene and contains a NotI site at its 5' end. The resulting PCR fragment is digested with NotI and gel-purified. Plasmid pBS-TPO1 is digested with NotI, which cleaves at a single site upstream of TPO exon 1 (Figure 3), and the digested DNA is ligated to the CMV promoter fragment prepared above and transformed into competent *E. coli* cells. Colonies containing inserts of the CMV promoter inserted at the NotI site of pBS-TPO1 are analyzed by restriction enzyme analysis to confirm the orientation of the insert, and one recombinant plasmid in which the CMV promoter is oriented such that the direction of transcription is towards TPO exon 1 is identified and designated pBS-TPO2.

Oligo 2.1 (SEQ ID NO: 5)

5' TTTTGCGGCC GCTCGAGGAC ATTGATTATT GACTAGT  
NotI XhoI

Oligo 2.2 (SEQ ID NO: 6)

5' TTTTGCGGCC GCCGGTACTT ACGTCACTCT TGGCAC  
NotI

Next, the neomycin phosphotransferase (*neo*) gene is inserted into pBS-TPO2 for use as a selectable marker in isolating stably transfected human cells. Plasmid pMC1neoPolyA [Thomas, K.R. and Capecchi, M.R. *Cell* 51:503-512 (1987); available from Stratagene Inc., La Jolla, CA] is digested with *Bam*HI and made blunt-ended by treatment with the Klenow fragment of *E. coli* DNA polymerase. The treated DNA is then ligated to a double-stranded 10 base pair *Cla*I linker of the sequence 5'GGATCGATCC, chosen such that the *Bam*HI site is not regenerated by the linker addition. The resulting DNA is digested with *Cla*I and the digested DNA is ligated under dilute conditions to promote recircularization and transformed into competent *E. coli* cells. Transformed colonies are analyzed by restriction enzyme digestion to identify cells containing a derivative of plasmid pMC1neoPolyA with an insertion of a *Cla*I site at the 3' end of the *neo* gene. This plasmid is designated pMC1neo-C. pMC1neo-C is digested with *Xho*I and *Sal*I and the approximately 1.1 kb fragment containing the *neo* expression unit is gel purified. Plasmid pBS-TPO2 is digested at the unique *Xho*I site which was introduced by PCR at the 5' end of the CMV promoter, and the digested DNA is ligated to the purified *Xho*I-*Sal*I fragment containing the *neo* gene and transformed into competent *E. coli* cells. Colonies containing inserts of the *neo* gene inserted at the *Xho*I site of pBS-TPO2 are analyzed by restriction enzyme analysis to confirm the orientation of the insert, and one recombinant plasmid in which the *neo* gene is oriented such that the direction of transcription is opposite to CMV is identified and designated pBS-TPO3.

Finally, the targeting construct pTPO1 is constructed by insertion of a *dhfr* expression unit (to select for

amplification in targeted human cells) at the *Cla*I site located at the 5' end of the *neo* gene of pBS-TPO3. To obtain a *dhfr* expression unit, the plasmid construct pF8CIS9080 [Eaton et al., *Biochemistry* 25: 8343-8347 (1986)] is digested with *Eco*RI and *Sal*I. A 2 kb fragment containing the *dhfr* expression unit is purified from this digest and made blunt by treatment with the Klenow fragment of DNA polymerase I. A *Cla*I linker (New England Biolabs, Beverly, MA) is then ligated to the blunted *dhfr* fragment. The products of this ligation are digested with *Cla*I ligated to *Cla*I digested pBS-TPO3. An aliquot of this ligation is transformed into *E. coli* and plated on ampicillin selection plates. Bacterial colonies are analyzed by restriction enzyme digestion to determine the orientation of the inserted *dhfr* fragment. One plasmid with *dhfr* in a transcriptional orientation opposite that of the *neo* gene is designated pRTPO1. For targeting to the *TPO* locus in cultured human cells, pRTPO1 is digested with *Bam*HI to separate the targeting fragment containing the targeting DNA, *neo* gene, *dhfr* gene, CMV promoter, and splice-donor site from the pBS plasmid backbone.

A second strategy for activation of the *TPO* gene is shown in Figure 7. In this strategy, a targeting fragment is introduced into the genome of recipient cells for insertion of a regulatory region, a non-coding exon, a splice-donor site, an intron, a splice-acceptor site, a second non-coding exon, and a functional, unpaired splice-donor site upstream of the *TPO* coding region. Specifically, the targeting construct from which this fragment is derived (pRTPO2) is designed to include a first targeting sequence homologous to sequences upstream of the *TPO* gene, an amplifiable marker gene, a selectable marker gene, a regulatory region, a CAP site, a non-coding exon, a

splice-donor site, an intron, a splice-acceptor site, a second non-coding exon, an unpaired splice-donor site, and a second targeting sequence corresponding to sequences downstream of the first targeting sequence but upstream of TPO exon 2. By this strategy, homologously recombinant cells produce an mRNA precursor which corresponds to the first and second non-coding exogenous exons separated by an intron, the second targeting sequence, any sequences between the second targeting sequence and exon 2 of the TPO gene, and the remaining exons, introns, and 3' untranslated regions of the TPO gene (Figure 7). Splicing of this message results in the fusion of the second non-coding exogenous exon to exon 2 of the endogenous TPO gene which, when translated, will produce TPO. In this strategy the first and second targeting sequences are upstream of the normal target gene, but this is not required (see below). The size of the intron in the targeting construct and thus the position of the regulatory region relative to the coding region of the gene may be varied to optimize the function of the regulatory region.

Plasmid pRTPO2 is constructed as follows: Based on the restriction map of the TPO upstream region (Figure 3), a 1.8 kb *Bam*HI-*Eco*RI fragment can be isolated from subclone pBS(X)/5'Thromb.8 (Example 1). This fragment is ligated to *Bam*HI and *Eco*RI digested plasmid pBS (Stratagene, Inc., La Jolla, CA) and transformed into competent *E. coli* cells to generate pBS-TPO4. This fragment includes TPO exon 1 but contains no TPO coding sequences.

Next, oligonucleotides 2.3 to 2.6 are used in PCR to fuse CMV IE promoter sequences beginning at nucleotide 546 and ending at nucleotide 2105 of Genbank sequence HS5MIEP to sequences from the TPO gene comprised of exon 1 and a portion of intron 1. The properties of these primers are

as follows: 2.3 (SEQ ID NO: 7) is a 30 base  
oligonucleotide homologous to a segment of the CMV IE  
promoter beginning at nucleotide 546 of Genbank sequence  
HS5MIEP (-614 relative to the cap site) and includes a XhoI  
5 site at its 5' end; 2.4 (SEQ ID NO: 8) and 2.5 (SEQ ID NO:  
9) are 60 nucleotide complementary primers which define the  
fusion of CMV (position 2100 of Genbank sequence HS5MIEP)  
and TPO (position -1881 relative to the TPO translation  
start site) sequences; 2.6 (SEQ ID NO: 10) is 27  
10 nucleotides in length and is homologous to TPO sequences  
ending in TPO intron 1 at position -1374 relative to the  
TPO translation start site and includes a natural ApaI  
site.

Oligo 2.3 (SEQ ID NO: 7)

15 5' TTTTCTCGAG GACATTGATT ATTGACTAGT  
XhoI

Oligo 2.4 (SEQ ID NO: 8)

5' catgggtcctt ttctgcagtc accgtccttg CTACCCATCT GCTCCCCAGA  
GGGCTGCCTG

20 Oligo 2.5 (SEQ ID NO: 9)

5' CAGGCAGCCC TCTGGGGAGC AGATGGGTAG caaggacggt gactgcagaa  
aagacccatg

Oligo 2.6 (SEQ ID NO: 10)

25 5' TTTTGGGCCC TCCTCCCATT ACCCTCT  
ApaI

Oligos 2.3-2.6: Bases in lower-case type denote CMV sequences; bases in upper-case type denote TPO sequences

These primers are used to amplify a 2.1 kb DNA fragment comprising a fusion of CMV IE and TPO sequences. The fusion fragment is created by first using oligos 2.3 and 2.4 to amplify a 1.6 kb fragment from hGH expression construct pXGH308, which has the CMV immediate-early (IE) gene promoter region beginning at nucleotide 546 and ending at nucleotide 2105 of Genbank sequence HS5MIEP fused to the hGH sequences beginning at nucleotide 5225 and ending at nucleotide 7322 of Genbank sequence HUMGHCSA. (The source of the CMV IE gene is not critical, and other CMV IE promoter-based plasmids may be used, or wild-type CMV DNA may be used.) Then, oligos 2.5 and 2.6 are used to amplify a 0.54 kb fragment containing portions of TPO exon 1 and TPO intron 1 from plasmid pBS(X)/5'Thromb.8 (Example 1). The two amplified fragments are then combined and further amplified using oligos 2.3 and 2.6. The resulting product, a 2.1 kb PCR fragment is digested with XhoI and ApaI and gel purified. Plasmid pMCneo-C (see above) is digested with SalI and XhoI and the 1.1 kb neo containing fragment is gel purified. The purified 2.1 kb PCR fragment and the 1.1 kb neo fragment are then mixed and ligated to pBS-TPO4 (above) which has been cut with SalI and ApaI. The ligation mixture is transformed into *E. coli* cells and a plasmid with a single insert of each the fusion fragment and the neo gene is identified, this plasmid having the SalI site at the 3' end of the neo gene regenerated by ligation to the SalI site in the polylinker of pBS-TPO4. The resulting plasmid is designated pBS-TPO5.

A *dhfr* expression unit (to select for amplification in targeted human cells) is then inserted at the ClaI site

located at the 5' end of the *neo* gene of pBS-TP05. The *dhfr* expression unit is isolated from plasmid pF8CIS9080 [Eaton et al., *Biochemistry* 25: 8343-8347 (1986)] by digestion with *EcoRI* and *SalI*. A 2 kb fragment containing the *dhfr* expression unit is purified from this digest and made blunt by treatment with the Klenow fragment of DNA polymerase I. A *ClaI* linker (New England Biolabs, Beverly, MA) is then ligated to the blunted *dhfr* fragment. The products of this ligation are digested with *ClaI* ligated to *ClaI* digested pBS-TP05. An aliquot of this ligation is transformed into *E. coli* and plated on ampicillin selection plates. Bacterial colonies are analyzed by restriction enzyme digestion to determine the orientation of the inserted *dhfr* fragment. One plasmid with *dhfr* in a transcriptional orientation opposite that of the *neo* gene is designated pBS-TP06.

To complete plasmid pRTPO2, plasmid pBS(X)/5'Thromb.8 (Example 1) is partially digested with *BamHI* and ligated to a *SalI* linker. The resulting DNA is then digested with *SalI* and *HindIII* and the 3.7 kb fragment consisting of sequences upstream of the *TPO* gene is isolated for use as a second targeting sequence. This fragment is ligated to *HindIII-SalI* digested pBS-TP06 to generate the targeting plasmid pRTPO2. For targeting to the *TPO* locus in cultured human cells, pRTPO2 is digested with *HindIII* and *EcoRI* to separate the targeting fragment containing the targeting DNA, *neo* gene, *dhfr* gene, and CMV promoter from the pBS plasmid backbone.

A third strategy for activation of the *TPO* gene is shown in Figure 8. In this strategy, a targeting fragment is introduced into the genome of recipient cells for replacement of the normal *TPO* regulatory region, *TPO* exon 1, *TPO* intron 1, and *TPO* exon 2 with an exogenous



regulatory region, a coding exon, and a functional, unpaired splice-donor site. Specifically, the targeting construct from which this fragment is derived (pRTPO3) is designed to include a first targeting sequence homologous to sequences upstream of the TPO gene, an amplifiable marker gene, a selectable marker gene, a regulatory region, a CAP site, an exon which includes sequences coding for the first 3 1/3 amino acids of the human growth hormone (hGH) signal peptide, an unpaired splice-donor site, and a second targeting sequence corresponding to TPO intron 2 sequences. By this strategy, homologously recombinant cells produce an mRNA precursor which corresponds to the exogenous coding exon, intron 2 of the TPO gene, exon 3 of the TPO gene, and the remaining exons, introns, and 3' untranslated regions of the TPO gene (Figure 8). Splicing of this message results in the fusion of the exogenous coding exon to exon 3 of the endogenous TPO gene which, when translated, will produce a fusion protein in which the first 3 amino acids of the signal peptide are derived from hGH. The signal peptide of this molecule is cleaved off prior to secretion from a cell to produce mature TPO. In this strategy the first targeting sequence is upstream of the normal target gene, while the second targeting sequence is within the gene, between exons 2 and 3. The position of the first targeting sequence and the amount of upstream DNA replaced or deleted by the targeting event may be varied to optimize the function of the regulatory region.

Plasmid pRTPO3 is constructed as follows:

Oligonucleotides 2.8 to 2.11 are used in PCR to fuse CMV IE promoter sequences beginning at nucleotide 546 and ending at nucleotide 1258 of Genbank sequence HS5MIEP to sequences from the human growth hormone gene which encode the first 3 1/3 amino acids of the hGH signal peptide, a splice donor

site, and the second intron of the TPO gene. The  
 properties of these primers are as follows: Oligo 2.8 (SEQ  
 ID NO: 11) is a 30 base oligonucleotide homologous to a  
 segment of the CMV IE promoter beginning at nucleotide 546  
 of Genbank sequence HS5MIEP (-614 relative to the cap site)  
 and includes an *Xho*I site at its 5' end; 2.9 (SEQ ID NO:  
 12) and 2.10 (SEQ ID NO: 13) are 69 nucleotide  
 complementary primers which define the fusion of CMV  
 (position 2100 of Genbank sequence HS5MIEP) and hGH  
 sequences (position -10 relative to the translation start  
 site of the hGH gene; see the hGH gene N sequence in  
 Genbank entry HUMGHCSA) sequences. These primers also  
 include the first 29 base pairs of TPO intron 2  
 (nucleotides +14 to +42 relative to the TPO translation  
 start site), which include the splice donor site; 2.11 (SEQ  
 ID NO: 14) is 45 nucleotides in length and is homologous to  
 TPO sequences in TPO intron 2 starting at position +182  
 relative to the TPO translation start site and extending  
 upstream, and includes a natural *Eco*RI site at its 5' end.

The fusion fragment is created by first using oligos  
 2.8 and 2.9 to amplify a 0.7 kb fragment from CMV viral DNA  
 containing a wild-type immediate early gene and promoter  
 sequence. (The source of the CMV IE gene is not critical,  
 and other CMV IE promoter-based plasmids may be used.)  
 Then, oligos 2.10 and 2.11 are used to amplify a 0.17 kb  
 fragment containing a portion of TPO intron 2 from plasmid  
 pBS(X)/5'Thromb.8 (Example 1). The two amplified fragments  
 are then combined and further amplified using oligos 2.8  
 and 2.11. The resulting product, a 0.9 kb PCR fragment is  
 digested with *Xho*I and *Eco*RI and gel purified. Next,  
 plasmid a pBS(X)/5'Thromb.8 (Example 1) is partially  
 digested with *Bam*HI and ligated to an *Xho*I linker. The  
 resulting DNA is then digested with *Xho*I and *Hind*III and

the 3.9 kb fragment consisting of sequences upstream of the TPO gene is isolated for use as a second targeting sequence. This fragment contains sequences from -5985 to -2095 relative to the TPO translation start site (Figure 3). The isolated fragment is then ligated in a mixture containing the 0.9 kb fusion fragment purified above and *HindIII* and *EcoRI* digested plasmid pBS (Stratagene, Inc., La Jolla, CA) and transformed into competent *E. coli* cells to generate pBS-TPO7.

For insertion of the neo selectable marker gene, plasmid pMC1neo-C (see above) is digested with *XhoI* and *SalI* and ligated to *XhoI* digested pBS-TPO7. The ligation mix is transformed into *E. coli* cells and colonies are analyzed by restriction enzyme analysis to identify a plasmid with a single insert of the neo gene oriented such that the direction of transcription is opposite to that of the CMV promoter. This plasmid is designated pBS-TPO8.

A *dhfr* expression unit (to select for amplification in targeted human cells) is then inserted at the *ClaI* site located at the 5' end of the neo gene of pBS-TPO8. The *dhfr* expression unit is isolated from plasmid pF8CIS9080 [Eaton et al., *Biochemistry* 25: 8343-8347 (1986)] by digestion with *EcoRI* and *SalI*. A 2 kb fragment containing the *dhfr* expression unit is purified from this digest and made blunt by treatment with the Klenow fragment of DNA polymerase I. A *ClaI* linker (New England Biolabs, Beverly, MA) is then ligated to the blunted *dhfr* fragment. The products of this ligation are digested with *ClaI* ligated to *ClaI* digested pBS-TPO8. An aliquot of this ligation is transformed into *E. coli* and plated on ampicillin selection plates. Bacterial colonies are analyzed by restriction enzyme digestion to determine the orientation of the inserted *dhfr* fragment. One plasmid with *dhfr* in a

transcriptional orientation opposite that of the *neo* gene is designated pRTPO3. For targeting to the TPO locus in cultured human cells, pRTPO3 is digested with *EcoRI* and *HindIII* to separate the targeting fragment containing the targeting DNA, *neo* gene, *dhfr* gene, CMV promoter, and hGH coding DNA from the pBS plasmid backbone.

Oligo 2.8 (SEQ ID NO: 11)

5' TTTTCTCGAG GACATTGATT ATTGACTAGT

*XhoI*

Oligo 2.9 (SEQ ID NO: 12)

5' cgcggtattcc ccgtgccaaag **CCTAGCGGCA ATGGCTACAG** GTGAGAACAC  
ACCTGAGGGG CTAGGGCCA

Oligo 2.10 (SEQ ID NO: 13)

5' TGGCCCTAGC CCCTCAGGTG TGTTCTCACC **TGTAGCCATT GCCGCTAGG**  
ttggcacggg gaatccgcg

Oligo 2.11 (SEQ ID NO: 14)

5' TTTTGAATTC CCATTCAGGA CCCAGACCTG AAACCCAGGG AATCC

*EcoRI*

Oligos 2.8-2.11: Bases in lower-case type denote CMV sequences; upper-case, non-bold bases denote TPO sequences; boldface bases denote hGH exon 1 sequences.

Other approaches for targeting and activation of the TPO gene may be employed. For example, the first and second targeting sequences may correspond to sequences in the first or second intron of the TPO gene, and the targeting sequences may include TPO coding sequences. In

any activation strategy, the second targeting sequence does not need to lie immediately adjacent to or near the first targeting sequence in the normal gene, such that portions of the gene's normal upstream region are deleted upon homologous recombination. Furthermore, one targeting sequence may be upstream of the gene and one may be within an exon or intron of the TPO gene.

A selectable marker gene is optional and the amplifiable marker gene is only required when amplification is desired. The amplifiable marker gene and selectable marker gene may be the same gene, their positions may be reversed, and one or both may be situated in the intron of the targeting construct. Amplifiable marker genes and selectable marker genes suitable for selection are described herein. The incorporation of a specific CAP site is optional. The regulatory region, CAP site, first non-coding exon, splice-donor site, intron, second non-coding exon, and splice acceptor site may be isolated as a complete unit from the human elongation factor-1a (EF-1a; Genbank sequence HUMEF1A) gene or the cytomegalovirus (CMV; Genbank sequence HEHCMVP1) immediate early region, or the components can be assembled from appropriate components isolated from different genes. In any case, either exogenous exon may be the same or different from the first exon of the normal TPO gene, and multiple non-coding exons may be present in the targeting construct.

As described herein, a number of selectable and amplifiable markers may be used in the targeting constructs, and the activation may be effected in a large number of cell-types.

EXAMPLE 3: In Vitro Production of TPO by Activation and Amplification of the TPO Gene in an Immortalized Cell Line

Transfection of primary, secondary, or immortalized human cells and isolation of homologously recombinant cells expressing TPO may be accomplished using the methods described in U.S. Serial No. 08/243,391 incorporated by reference. Homologously recombinant cells may be identified by PCR screening strategy as exemplified therein and in published methods available to one skilled in the art (see, for example, Kim, H-S and Smithies, O., *Nucl. Acids Res.* 16:8887-8903 (1988)). The identification of cells expressing TPO may also be accomplished using a variety of assays based on the structure or properties of TPO. For example, TPO may be functionally identified by an in vitro or in vivo megakaryocytopoiesis assay (de Sauvage et al., *Nature* 369:533-538 (1994)). Alternatively, TPO may be assayed by the stimulation of proliferation of cells expressing the c-mpl ligand, the receptor for TPO. In this assay, cells such as Ba/F3-mpl cells (de Sauvage et al., *Nature* 369:533-538 (1994)), are exposed to TPO and cell proliferation is monitored by <sup>3</sup>H-thymidine uptake. TPO may also be assayed through its effects on in vivo platelet production, either by direct platelet counts or by incorporation of <sup>35</sup>S into platelets. Finally, peptides corresponding to portions of the TPO molecule may be synthesized in order to generate anti-TPO antibodies for use in an ELISA assay.

The isolation of cells containing amplified copies of the amplifiable marker gene and the activated TPO locus is performed as described in U.S. Serial No.: 07/985,586 incorporated by reference.

EXAMPLE 4: Cloning of the Human DNase I Gene and  
Identification of the 5' Flanking Sequences

The human DNase I gene was isolated from a human genomic DNA library. The library (Clontech, Palo Alto, CA; Cat. #HL1006d) was constructed by cloning MboI partially digested male leukocyte DNA into the BamHI site of the bacteriophage lambda vector EMBL3. For library screening, a DNA probe was isolated by PCR amplification of human genomic DNA using oligonucleotides 4.1 and 4.2.

Oligo 4.1 (SEQ ID NO: 15)

5' TGCCTTGAAG TGCTTCTTCA

Oligo 4.2 (SEQ ID NO: 16)

5' CCTCAGAGAT GACGAGAATG C

These primers were designed based on the published DNase I mRNA sequence (Shak S. et al., *Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)). The amplified probe (probe A; 126 bp) was labeled with <sup>32</sup>P-dCTP by PCR and used to screen a bacteriophage lambda genomic DNA library. The filters were hybridized for 16 hours at 68°C in 125 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 250 mM NaCl, 10% PEG 8000, 7% SDS, 1 mM EDTA. Filters were washed two times in 500 ml of 20 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 5% SDS, 1 mM EDTA, followed by 4 washes in 500 ml of 20 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 1% SDS, 1 mM EDTA. The wash buffers were preheated to 56°C and washing was performed at room temperature on a rotary shaker for approximately 5 minutes per wash. The hybridization signals were visualized by autoradiography at -80°C with an intensifying screen. In this experiment, approximately 1 x



10<sup>6</sup> phage were screened and 18 positive signals were obtained. Bacteriophage plaques corresponding to 10 of the positive signals were plated at low density and subjected to a second round of screening using probe A. Four of the phage (designated 2a, 3b, 4c and 14a) gave positive hybridization signals following the secondary screening and were retained for further analysis. DNA was isolated from the plaque purified phage following amplification and subsequent purification by cesium chloride gradient ultracentrifugation (Yamamoto, K.R. et al., *Virology* 40:734 (1970)). Library screening, plaque purification of recombinant bacteriophage and isolation of bacteriophage DNA was performed using standard methods (Ausubel et al., *Current Protocols in Molecular Biology*. Wiley, New York, NY (1987)).

Based on restriction enzyme digestion and Southern blot analysis using probe A, two of the phage (4c and 14a) contain a common *HincII* fragment of approximately 8 kb which encompasses exon 1, intron 1, exon 2, coding and non-coding sequences corresponding to intron 2 and downstream *DNase I* exons, as well as approximately 4 kb of non-transcribed DNA lying upstream of *DNase I* exon I. This fragment was isolated from one genomic clone (4c) and subcloned into pBSIISK<sup>+</sup> (Stratagene Inc., La Jolla, CA) for further analysis. Restriction enzyme mapping of the resultant clone, pBS/ 4C.2Hinc2, was used to generate the restriction map shown in Figure 9. The nucleotide sequence of the non-transcribed *DNase I* 5' region lying upstream of the 5' end of the known cDNA sequence is shown in Figure 10 (SEQ ID NO: 17). The nucleotide sequence lying downstream of the 5' end of the known cDNA sequence, including exon 1, intron 1 and part of exon 2 is shown in Figure 11 (SEQ ID NO: 18). Comparison of the cloned genomic sequence



presented here, with the published cDNA sequence (Shak, S. et al., *Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)) reveals that the 5' end of the *DNase I* gene consists of a non-coding exon (exon 1) of 142 bp and a second exon (exon 2) which is at least 341 bp. Exon 2 encodes a 22 amino acid signal sequence and a portion of the mature *DNase I* peptide, beginning with an AUG translational initiation codon which lies 1 bp downstream of the 5' end of exon 2. Exons 1 and 2 are separated by intron 1 which is 336 bp in length.

EXAMPLE 5: Construction of Targeting Plasmids for  
Activation and Amplification of the *DNase I*  
Gene

The activation of the *DNase I* gene can be accomplished by the strategy outlined in Figure 12. In this strategy, a targeting fragment is introduced into the genome of recipient cells for insertion of a regulatory region, a non-coding exon and a functional unpaired splice-donor site upstream of the *DNase I* coding region. Specifically, the targeting construct from which this fragment is derived (pDNase1), is designed to include a 5' targeting sequence homologous to sequences upstream of the *DNase I* gene, a selectable marker gene, an amplifiable marker gene, a regulatory region, a CAP site, a non-coding exon, an unpaired splice-donor site, and a 3' targeting sequence corresponding to sequences downstream of the 5' targeting sequence but upstream of *DNase I* exon 1. According to this strategy, integration of the targeting construct by homologous recombination generates recombinant cells producing an mRNA precursor which includes the non-coding exon introduced upstream of the *DNase I* gene, the 3' targeting sequence, any sequences between the 3' targeting

sequence and exon 2 of the *DNase I* gene, and the remaining  
exons, introns and 3' untranslated regions of the *DNase I*  
gene (Figure 12). Splicing of this transcript results in  
the fusion of the exogenous non-coding exon to exon 2 of  
the endogenous *DNase I* gene. *DNase I* is produced by  
translation of the mature mRNA. According to this  
strategy, both the 5' and 3' targeting sequences are  
upstream of the endogenous target gene. The size of the  
chimeric intron in the targeting construct, which is  
dictated by the position of the regulatory region relative  
to the coding sequence, may be varied to optimize the  
function of the regulatory region.

Plasmid pCND1, which contains the activation cassette,  
is constructed as follows: A 1555 bp (size includes a 9 bp  
synthetic *HindIII* recognition site at the 5' end of oligo  
5.2) fragment is amplified using oligos 5.1 and 5.2. The  
amplified fragment encompasses the CMV IE promoter, CMV IE  
exon 1 (non-coding exon) and 827 bp of CMV IE intron 1,  
beginning at nucleotide 172,783 and ending at nucleotide  
174,328 of EMBL sequence X17403 ((Human cytomegalovirus  
strain AD169). (The source of the CMV IE gene is not  
critical, and CMV IE promoter-based plasmids or wild-type  
CMV DNA may be used.) Oligo 5.1 (21 bp, SEQ ID NO: 19)  
hybridizes to the CMV IE promoter at -598 relative to the  
CAP site (EMBL sequence X17403). Oligo 5.2 (32 bp, SEQ ID  
NO: 20) contains 23 nucleotides which hybridize to the CMV  
IE promoter at +946 relative to the CAP site, the  
additional 9 bp at the 5' end of the oligo create a  
synthetic *HindIII* recognition sequence. The 1555 bp PCR  
product is digested with *HindIII* and the resultant 1551 bp  
fragment is purified and used in the ligation described  
below. Next, the neomycin phosphotransferase (*neo*) gene is  
isolated from plasmid pBSneo for use as a selectable marker

for the isolation of stably transfected human cells. The neo gene in plasmid pBSneo was obtained by *Bam*HI and *Xho*I digestion of pMC1neo-polyA (Thomas, K.R. and Capecchi, M.R. *Cell* 51:503-512 (1987)). Plasmid pMC1neo-polyA was  
5 digested with *Bam*HI and made blunt ended with the Klenow fragment of *E. coli* DNA polymerase I. The resulting DNA was digested with *Xho*I, and the blunt-ended *Bam*HI-*Xho*I fragment was cloned into *Hinc*II and *Xho*I digested plasmid pBSIISK<sup>+</sup>. For isolation of the neo gene harbored on  
10 pBSneo, plasmid pBSneo is digested with *Xho*I and made blunt-ended by treatment with the Klenow fragment of *E. coli* DNA polymerase I. The resulting DNA is digested with *Hind*III and an 1165 bp fragment containing the neo expression unit is gel purified. The 1165 bp neo fragment  
15 and the 1551 bp CMV promoter fragment are ligated, the ligation products are digested with *Hind*III and the 2716 bp *Hind*III fragment, resulting from blunt-end ligation of the two fragments, is gel purified. The 2716 bp *Hind*III product is ligated to *Hind*III digested plasmid pBSIISK<sup>+</sup>  
20 (Stratagene Inc., La Jolla, CA) and electroporated into *E. coli*. Colonies containing inserts in the *Hind*III site of pBSIISK<sup>+</sup> are analyzed by restriction enzyme analysis to confirm the orientation of the insert. One recombinant plasmid in which the CMV promoter is oriented such that the  
25 oligo 5.2 sequences (+946 relative to the CMV IE CAP site) are proximal to the *Sal*I recognition sequence in the pBSIISK<sup>+</sup> polylinker, is identified and designated pCN1.

Oligo 5.1 (SEQ ID NO: 19)

5' GACATTGATT ATTGACTAGT T

30 Oligo 5.2 (SEQ ID NO: 20)

5' TTTAAGCTTC TGCAGAAAAG ACCCATGGAA AG

Next, the *dhfr* expression unit is inserted at a *Cla*I site which is located at the 3' end of the *neo* gene of pCN1. The *dhfr* expression unit is obtained by *Eco*RI and *Sal*I digestion of plasmid pF8CIS9080 (Eaton et al., *Biochemistry* 25:8343-8347 (1986)). The resultant 2 kb fragment is purified from the digest and made blunt with the Klenow fragment of *E. coli* DNA polymerase I. A *Cla*I linker (5' CCATCGATGG (NEB 1088; New England Biolabs, Beverly, MA) is ligated to the blunt-end *dhfr* fragment and the ligation products are digested with *Cla*I. pCN1 is digested with *Cla*I, and the *Cla*I *dhfr* containing fragment is ligated into *Cla*I site of pCN1. An aliquot of the ligation reaction is electroporated into *E. coli* and colonies harboring inserts in a *Cla*I site of pCN1 are analyzed by restriction enzyme analysis to determine the site of insertion and the orientation of the insert. A plasmid with the *dhfr* expression unit at the 3' end of the *neo* gene and with the same transcriptional orientation as that of the *neo* gene is identified and designated pCND1.

Plasmid pDNase1 is constructed as follows: Based on the restriction map of the upstream region of the *DNase I* gene (Figure 9), a 664 bp *Bam*HI fragment (-1161 to -498 in figure 8) can be isolated from subclone pBS/4C.2Hinc2. This fragment is ligated to *Bam*HI digested plasmid pBSIISK<sup>+</sup>dApaI (modification of pBSIISK<sup>+</sup>; Stratagene Inc., La Jolla, CA) in which the *Apa*I recognition sequence in the polylinker is destroyed. pBSIISK<sup>+</sup>dApaI is constructed by digesting pBSIISK<sup>+</sup> with *Apa*I, conversion of the cohesive-ends to blunt-ends with T4 DNA polymerase and ligation to generate the circular plasmid. Following ligation of the 664 bp *Bam*HI fragment into pBSIISK<sup>+</sup>dApaI, the ligation products are electroporated into *E. coli* cells to generate pBS-DNase1. The sequences contained in this

fragment reside upstream of *DNase I* exon 1, position -1162 to -498 with respect to the AUG translational initiation codon (nucleotide +1). The activation cassette which contains the CMV immediate-early (IE) promoter region, the CMV IE CAP site, a non-coding exon, an unpaired splice donor site, the neomycin phosphotransferase (*neo*) selectable marker gene and *dhfr* expression unit (to select for amplification in targeted human cells) is cloned into the unique *ApaI* site of the 664 bp *BamHI* fragment (*DNase I* upstream region) in pBS-DNase1 (see Figure 12). Specifically, plasmid pCND1 which contains the activation cassette, is digested with *SalI* which cuts downstream of the *dhfr* expression unit and *EspI* which cuts 242 bp downstream of the CMV IE CAP site. A 3,955 bp *SalI-EspI* fragment containing the activation cassette is purified from this digest and the cohesive-ends are made blunt by treatment with the Klenow fragment of *E. coli* DNA polymerase I. This fragment is ligated to plasmid pBS-DNase1, which has been digested with *ApaI* and made blunt-ended by treatment with T4 DNA polymerase I, and electroporated into *E. coli*. Colonies containing inserts of the activation cassette inserted at the blunt-ended *ApaI* site of pBS-DNase 1 are analyzed by restriction enzyme analysis to confirm the orientation of the insert. One recombinant plasmid in which the CMV promoter is oriented such that the direction of transcription is towards *DNase I* exon 1 is identified and designated pDNase1.

Plasmid pDNase1 is digested with *BamHI* for transfection into human cells. Transfection of primary, secondary, or immortalized human cells and isolation of homologously recombinant cells expressing *DNase I* may be accomplished using the methods described in U.S. Serial No. 08/243,391 and incorporated herein by reference.

Homologously recombinant cells may be identified by PCR screening strategy as exemplified therein and in published methods available to one skilled in the art (see, for example, Kim, H-S and Smithies, O., *Nucl. Acids Res.* 16:8887-8903 (1988)). The identification of cells expressing DNase I may also be accomplished using a variety of assays based on the structure or properties of DNase I. For example, DNase I may be functionally identified by an in vitro enzyme assay (cf. Kunitz, *J. Gen. Physiol.* 33: 349 (1950); McDonald, *Meth. Enzymol.* 2:437 (1955)) or by the use of anti-DNase I antibodies in an ELISA assay.

The isolation of cells containing amplified copies of the amplifiable marker gene and the activated DNase I locus is performed as described in U.S. Serial No.: 07/985,586 incorporated herein by reference.

EXAMPLE 6: Cloning of the Human  $\beta$ -Interferon Gene and Identification of the 5' Flanking Sequences

The human  $\beta$ -interferon gene was isolated from a human genomic DNA library. The library (Clontech, Palo Alto, CA; Cat. #HL1006d) was constructed by cloning *Mbo*I partially digested male leukocyte DNA into the *Bam*HI site of the bacteriophage lambda vector EMBL3. For library screening, a DNA probe was isolated by PCR amplification of human genomic DNA using oligonucleotides 6.1 and 6.2

Oligo 6.1 (SEQ ID NO: 21)  
5' TGCTCTGGCA CAACAGGTAG

Oligo 6.2 (SEQ ID NO: 22)  
5' CATAGATGGT CAATGCGGC

These primers were designed based on the published  $\beta$ -interferon mRNA sequence (May, L.T. and Sehgal, P.B., J. *Interferon Res.* 5:521-526 (1985)). The amplified probe (probe A; 290 bp) was labeled with  $^{32}\text{P}$ -dCTP by PCR and used to screen a bacteriophage lambda genomic DNA library. The filters were hybridized for 16 hours at 68°C in 125 mM  $\text{Na}_2\text{HPO}_4$  (pH 7.2), 250 mM NaCl, 10% PEG 8000, 7% SDS, 1 mM EDTA. Filters were washed two times in 500 ml of 20 mM  $\text{Na}_2\text{HPO}_4$  (pH 7.2), 5% SDS, 1 mM EDTA, followed by 4 washes in 500 ml of 20 mM  $\text{Na}_2\text{HPO}_4$  (pH 7.2), 1% SDS, 1 mM EDTA. The wash buffers were preheated to 56°C and washing was performed at room temperature on a rotary shaker for approximately 5 minutes per wash. The hybridization signals were visualized by autoradiography at -80°C with an intensifying screen. In this experiment, approximately  $1 \times 10^6$  phage were screened and 6 positive signals were obtained. Bacteriophage plaques corresponding to the positive signals were plated at low density and subjected to a second round of screening using probe A. Five of the phage (designated 1a, 2a, 2b, 11a, and 12a) gave positive hybridization signals following the secondary screening and were retained for further analysis. DNA was isolated from the plaque purified phage following amplification and subsequent purification by cesium chloride gradient ultracentrifugation (Yamamoto, K.R. et al., *Virology* 40:734 (1970)). Library screening, plaque purification of recombinant bacteriophage and isolation of bacteriophage DNA was performed using standard methods (Ausubel et al., *Current Protocols in Molecular Biology*. Wiley, New York, NY (1987)).

Based on restriction enzyme digestion and Southern blot analysis using probe A, all five of the phage (1a, 2a, 2b, 11a, and 12a) were shown to contain a common *Hind*III



fragment of approximately 10 kb which encompasses the entire sequence coding for  $\beta$ -interferon (561 bp), 666 bp of 3' untranslated sequence and approximately 9 kb of non-transcribed DNA lying upstream of the  $\beta$ -interferon gene. This fragment was isolated from one genomic clone (1a) and subcloned into pBSIISK<sup>+</sup> (Stratagene Inc., La Jolla, CA) for further analysis. The resultant clones, pBS-H3/Bint.11-3 and pBS-H3/Bint.11-21, harbor the 10 kb *Hind*III fragment in opposite orientations with respect to the plasmid backbone. Restriction enzyme mapping was used to generate the restriction map shown in Figure 13. The nucleotide sequence of 8,355 bp of DNA lying upstream of the previously reported sequence (Genbank entry HUMIFNB1F) is shown in Figure 14 (SEQ ID NO: 23). The nucleotide sequence corresponding to 356 bp of DNA upstream of the  $\beta$ -interferon coding region, the  $\beta$ -interferon coding region, and 666 bp of 3' untranslated sequence is shown in Figure 15 (SEQ ID NO: 24). Comparison of the cloned genomic sequence presented here, with the published cDNA sequence (May, L.T. and Sehgal, P.B., *J. Interferon Res.* 5:521-526 (1985)) confirms that the  $\beta$ -interferon gene consists of a 561 bp coding region which is co-linear with its cognate mRNA (lacks introns). The  $\beta$ -interferon gene encodes a 21 amino acid signal sequence and a 120 amino acid mature peptide, beginning with an AUG translational initiation codon which lies 82 bp downstream of the CAP site.

EXAMPLE 7: Construction of Targeting Plasmids for Activation and Amplification of the  $\beta$ -Interferon Gene

The activation of the  $\beta$ -interferon gene can be accomplished by the strategy outlined in Figure 16. In this strategy, a targeting fragment is introduced into the



genome of recipient cells for replacement of the endogenous  $\beta$ -interferon regulatory region with an exogenous regulatory region, a non-coding exon, an intron, and chimeric exon sequences consisting of sequences from a noncoding exon (derived from exon 2 of the CMV IE gene) and sequences from the  $\beta$ -interferon 5' noncoding region. Specifically, the targeting construct from which this fragment is derived (pIFN $\beta$ -1) is designed to include a 5' targeting sequence homologous to sequences upstream of the  $\beta$ -interferon gene, a selectable marker gene, an amplifiable marker gene, a regulatory region, a CAP site, a non-coding exon, an intron, chimeric exon sequences consisting of CMV IE exon 2 sequences and  $\beta$ -interferon 5' noncoding DNA, and a 3' targeting sequence homologous to DNA upstream of the  $\beta$ -interferon coding region. According to this strategy, integration of the targeting construct by homologous recombination generates recombinant cells producing an mRNA precursor which includes the non-coding exon introduced upstream of the  $\beta$ -interferon gene, an intron, the chimeric exon which fuses CMV IE exon sequences to  $\beta$ -interferon 5' noncoding sequences and the entire  $\beta$ -interferon coding region, and 3' untranslated regions of the  $\beta$ -interferon gene (Figure 16). The chimeric exon consists of 17 bp of CMV IE exon 2 (position 172,782 to 172,766 of EMBL sequence X17403) joined to the 5' flanking region of the  $\beta$ -interferon gene (position -173 with respect to the AUG translational initiation codon). Splicing of this transcript results in the fusion of the exogenous non-coding exon to exon 2 which includes the complete coding sequence of the endogenous  $\beta$ -interferon gene.  $\beta$ -interferon is produced by translation of the mature mRNA. According to this strategy, the 5' targeting sequence is upstream of the endogenous target gene and the 3' targeting

sequence is in the  $\beta$ -interferon 5' noncoding region. The position of the regulatory region relative to the 5' flanking sequence, may be varied (e.g. by altering the size of the intron in the targeting construct) to optimize the function of the regulatory region.

Plasmid pIFN $\beta$ -1 is constructed as follows: A 182 bp fragment (size includes a 9 bp synthetic *Bam*HI recognition site at the 5' end of Oligo 7.1) is amplified from pBS-H3/Bint.11-3 using oligos 7.1 and 7.2. The amplified fragment serves as the 3' targeting sequence (Figure 16). Oligo 7.1 (21 bp, SEQ ID NO: 25) hybridizes to the  $\beta$ -interferon 5' non-transcribed region at position -173 with respect to the  $\beta$ -interferon AUG translational initiation codon (Figure 15). Oligo 7.2 (30 bp, SEQ ID NO: 26) contains 21 nucleotides which hybridize to the  $\beta$ -interferon 5' untranslated region at position -1 relative to the AUG translational start codon (see Figure 16), with the additional 9 bp at the 5' end of the oligo creating a synthetic *Bam*HI recognition sequence. The 182 bp PCR product is purified and used in the ligation described below. Next, a 1571 bp (size includes an 8 bp synthetic *Sma*I recognition sequence at the 5' end of oligo 7.3) fragment is amplified using oligos 7.3 and 7.4. The amplified fragment encompasses the CMV IE promoter, CMV IE exon 1 (non-coding exon), CMV IE intron 1 and 17 bp of CMV IE exon 2, beginning at nucleotide 174,328 and ending at nucleotide 172,766 of EMBL sequence X17403 (Human cytomegalovirus strain AD 169). (The source of the CMV IE gene is not critical, and CMV IE promoter-based plasmids or wild type CMV DNA may be used). Oligo 7.3 (29 bp, SEQ ID NO: 27) contains 21 nucleotides which hybridize to the CMV IE promoter at -598 relative to the CAP site (EMBL sequence X17403), the 5' end of the oligo also contains a 8 bp

synthetic *Sma*I recognition sequence. Oligo 7.4 (21 bp, SEQ ID NO: 28) hybridizes to the CMV IE promoter at +965 relative to the CAP site. The 1571 bp PCR product containing the CMV IE promoter, CMV IE exon 1, CMV IE intron 1 and 23 bp of CMV IE exon 2, is gel purified and ligated to the 182 bp fragment containing the  $\beta$ -interferon 5' flanking region. The ligation products are digested with *Bam*HI and *Sma*I, and the 1742 bp *Sma*I-*Bam*HI fragment, resulting from ligation of  $\beta$ -interferon sequences (position -173 with respect to the AUG translational initiation codon) to CMV IE sequences (-598 relative to the CMV IE CAP site), is gel purified. The 1742 bp *Sma*I-*Bam*HI fragment is ligated to *Bam*HI and *Sma*I digested plasmid pBSIISK<sup>+</sup> (Stratagene Inc., La Jolla, CA) and electroporated into *E. coli*. Colonies containing inserts in pBSIISK<sup>+</sup> are analyzed by restriction enzyme analysis to confirm the structure of the insert. One recombinant plasmid is identified and designated pBS-CB.

Oligo 7.1 (SEQ ID NO: 25)

5' TGACATAGGA AAAGTGAAG G

Oligo 7.2 (SEQ ID NO: 26)

5' TTTGGATCCG TTGACAACAC GAACAGTGTC G

Oligo 7.3 (SEQ ID NO: 27)

5' TTTCCCGGGA CATTGATTAT TGAAGTAGTT

Oligo 7.4 (SEQ ID NO: 28)

5' CGTGTCAGG ACGGTGACTG C

The neomycin phosphotransferase (*neo*) gene is isolated from plasmid pBSneo for use as a selectable marker for the

isolation of stably transfected human cells. The neo gene in plasmid pBSneo was obtained by *Bam*HI and *Xho*I digestion of pMC1neo-polyA (Thomas, K.R. and Capecchi, M.R., *Cell* 51:503-512 (1987)). Plasmid pMC1neo-polyA was digested with *Bam*HI and made blunt ended with the Klenow fragment of *E. coli* DNA polymerase I. The resulting DNA was digested with *Xho*I, and the blunt-ended *Bam*HI-*Xho*I fragment was cloned into *Hinc*II and *Xho*I digested plasmid pBSIISK<sup>+</sup>. For isolation of the neo gene harbored on pBSneo, plasmid pBSneo is digested with *Xho*I and made blunt-ended by treatment with the Klenow fragment of *E. coli* DNA polymerase I. The resulting DNA is digested with *Hind*III and a 1165 bp fragment containing the neo expression unit is gel purified. The 1165 bp fragment is ligated to *Sma*I and *Hind*III digested plasmid pBS-CB and electroporated into *E. coli*. Colonies containing inserts in pBS-CB are analyzed by restriction enzyme analysis to confirm the orientation of the insert. One recombinant plasmid is identified and designated pBS-CBN.

Next, the *dhfr* expression unit is inserted at the *Cla*I site which is located at the 3' end of the neo gene of pBS-CBN. The *dhfr* expression unit is obtained by *Eco*RI and *Sal*I digestion of plasmid pF8CIS9080 (Eaton et al., *Biochemistry* 25:8343-8347 (1986)). The resultant 2 kb fragment is purified from the digest and made blunt with the Klenow fragment of *E. coli* DNA polymerase I. A *Cla*I linker (5' CCATCGATGG; NEB 1088, New England Biolabs, Beverly, MA) is ligated to the blunt-end *dhfr* fragment, the ligation products are digested with *Cla*I and purified. The *Cla*I *dhfr* containing fragment is ligated into *Cla*I digested plasmid pBS-CBN. An aliquot of the ligation reaction is electroporated into *E. coli* and colonies harboring inserts in a *Cla*I site of pBS-CBN are analyzed by restriction

enzyme analysis to determine the site of insertion and the orientation of the insert. A plasmid with the *dhfr* expression unit at the 3' end of the *neo* gene and with the same transcriptional orientation as that of the *neo* gene is identified and designated pBS-CBND.

Finally, the targeting construct is constructed by insertion of the 5' targeting sequence (Figure 16) in the unique *Sal*I site located at the 3' end of the *dhfr* expression unit in plasmid pBS-CBND. To obtain the 5' targeting sequence, the plasmid pBS-H3/Bint.11-3 is digested with *Eco*RI and *Pvu*II and the resultant 1.2 kb fragment is purified, ligated to *Eco*RI-*Sma*I digested plasmid pBSIISK<sup>+</sup> (Stratagene Inc., La, Jolla, CA) and electroporated into *E. coli*. Colonies containing inserts in pBSIISK<sup>+</sup> are analyzed by restriction enzyme analysis, and one plasmid containing the insert is retained and designated pBS-BI5. Plasmid pBS-BI5 is digested with *Spe*I and *Eco*RV and made blunt-ended with the Klenow fragment of DNA polymerase I. The resulting 1.2 kb fragment is ligated to *Sal*I digested plasmid pBS-CBND, which has been made blunt-ended with the Klenow fragment of *E. coli* DNA polymerase I. An aliquot of the blunt-end ligation reaction is electroporated into *E. coli* and colonies harboring inserts in the *Sal*I site of pBS-CBND are analyzed by restriction enzyme analysis to determine the orientation of the insert. A plasmid with the *Eco*RI site at the 3' end of the *dhfr* expression unit is identified and designated pIFN $\beta$ -1.

Plasmid pIFN $\beta$ -1 is digested with *Bam*HI for transfection into human cells. Transfection of primary, secondary, or immortalized human cells and isolation of homologously recombinant cells expressing  $\beta$ -interferon may be accomplished using the methods described in U.S. Serial

No. 08/243,391 and incorporated herein by reference.  
Homologously recombinant cells may be identified by PCR  
screening strategy as exemplified therein and in published  
methods available to one skilled in the art (see, for  
5 example, Kim, H-S and Smithies, O., *Nucl. Acids Res.*  
16:8887-8903 (1988)). The identification of cells  
expressing  $\beta$ -interferon may also be accomplished using a  
variety of assays based on the structure or properties of  
 $\beta$ -interferon. For example,  $\beta$ -interferon may be identified  
10 by an in vitro reverse passive hemagglutination assay  
(Accurate Chemical Corp., Westbury, NY), stimulation of  
superoxide anion production by mouse peritoneal macrophages  
(Colligan, J. E. et al. *Current Protocols in Immunology*,  
Wiley, New York, NY. (1994), or by using anti- $\beta$ -interferon  
15 antibodies in an ELISA assay.

The isolation of cells containing amplified copies of  
the amplifiable marker gene and the activated  $\beta$ -interferon  
locus is performed as described in U.S. Serial No.:  
07/985,586 incorporated herein by reference.

#### 20 Equivalents

Those skilled in the art will recognize, or be able to  
ascertain using not more than routine experimentation, many  
equivalents to the specific embodiments of the invention  
described herein. Such equivalents are intended to be  
25 encompassed by the following claims.

## CLAIMS

1. A DNA construct capable of altering the expression of a gene encoding thrombopoietin when inserted by homologous recombination into chromosomal DNA of a cell,  
5 said construct comprising:

(a) a targeting sequence comprising DNA which hybridizes to genomic DNA within or upstream of the thrombopoietin gene;

(b) a regulatory sequence;

10 (c) an exon; and

(d) an unpaired splice-donor site.

2. The DNA construct of claim 1 wherein the regulatory sequence comprises a promoter.

3. The DNA construct of Claim 2 further comprising a  
15 selectable marker gene.

4. The DNA construct of Claim 2 further comprising an amplifiable marker gene.

5. The DNA construct of Claim 1 further comprising a second targeting sequence comprising DNA which hybridizes  
20 to genomic DNA within or upstream of the thrombopoietin gene.

6. The DNA construct of Claim 1 wherein the targeting sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4 or fragments thereof or a  
25 sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4 or fragments thereof.



7. The DNA construct of Claim 6 wherein the targeting sequence is a fragment of SEQ ID NO: 3 and is at least about 20 base pairs.

8. The DNA construct of Claim 6 wherein the targeting sequence is a fragment of SEQ ID NO: 4 and is at least about 20 base pairs.

9. The DNA construct of Claim 8 wherein the targeting sequence is at least about 20 base pairs and is a sequence between about nucleotides -1815 to -145, 14 to 245, or 374 to 570 of Figure 5 (SEQ ID NO: 4).

10. An isolated DNA molecule of at least about 20 base pairs selected from the group consisting of SEQ ID NO: 3, a fragment thereof, and a sequence which hybridizes to SEQ ID NO: 3.

11. An isolated DNA molecule of at least about 20 base pairs which is selected from the group consisting of a sequence between about nucleotides -1815 to -145, 14 to 245, or 374 to 570 of Figure 5 (SEQ ID NO: 4), and a sequence which hybridizes to a sequence between about nucleotides -1815 to -145, 14 to 245, or 374 to 570 of Figure 5 (SEQ ID NO: 4).

12. A method of producing a homologously recombinant cell wherein the expression of the thrombopoietin gene is altered, comprising the steps of:

- (a) transfecting a cell containing the thrombopoietin gene with the DNA construct of one of Claims 1-9; and
- (b) maintaining the transfected cell under conditions appropriate for homologous recombination.

13. A homologously recombinant cell produced by the method of Claim 12.

14. A homologously recombinant cell which expresses thrombopoietin comprising an exogenous regulatory region,  
5 an exogenous exon, and an exogenous unpaired splice-donor site operatively linked to an endogenous splice acceptor site of the thrombopoietin gene.

15. The homologously recombinant cell of Claim 14 wherein the exogenous regulatory region, the exogenous  
10 exon, and the exogenous unpaired splice-donor site are operatively linked to the endogenous splice acceptor site of the second or third exon of the thrombopoietin gene.

16. A method for producing thrombopoietin comprising the steps of maintaining the homologously recombinant cell  
15 of Claim 14 or 15 under conditions appropriate for the production of thrombopoietin.

17. A method for producing thrombopoietin wherein the expression of the thrombopoietin gene is altered,  
comprising the steps of:

20 (a) transfecting a cell containing the thrombopoietin gene with the DNA construct of one of Claims 1-9; and  
(b) maintaining the transfected cell under conditions appropriate for homologous recombination; and  
(c) maintaining the homologously recombinant cell  
25 produced in step (b) under conditions appropriate for the production of thrombopoietin.

18. A thrombopoietin produced by the method of Claim 17.

19. A pharmaceutical composition comprising the thrombopoietin of Claim 18.

20. A method of providing thrombopoietin to a mammal in need thereof comprising administering homologously recombinant cells of Claim 14 or 15 in sufficient number to produce a therapeutically effective amount of thrombopoietin in the mammal.

21. A DNA construct capable of altering the expression of a gene encoding DNase I when inserted by homologous recombination into chromosomal DNA of a cell, said construct comprising:

(a) a targeting sequence comprising DNA which hybridizes to genomic DNA within or upstream of the DNase I gene;

(b) a regulatory sequence;

(c) an exon; and

(d) an unpaired splice-donor site.

22. The DNA construct of claim 21 wherein the regulatory sequence comprises a promoter.

23. The DNA construct of Claim 22 further comprising a selectable marker gene.

24. The DNA construct of Claim 22 further comprising an amplifiable marker gene.

25. The DNA construct of Claim 21 further comprising a second targeting sequence comprising DNA which hybridizes to genomic DNA within or upstream of the DNase I gene.

26. The DNA construct of Claim 21 wherein the targeting sequence is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18 or fragments thereof or a sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18 or fragments thereof.

27. The DNA construct of Claim 26 wherein the targeting sequence is a fragment of SEQ ID NO: 17 and is at least about 20 base pairs.

28. The DNA construct of Claim 26 wherein the targeting sequence is a fragment of SEQ ID NO: 18 and is at least about 20 base pairs.

29. The DNA construct of Claim 28 wherein the targeting sequence is at least about 20 base pairs and is a sequence between about nucleotides -328 to -2 of Figure 11 (SEQ ID NO: 18).

30. An isolated DNA molecule of at least about 20 base pairs selected from the group consisting of SEQ ID NO: 17, a fragment thereof, and a sequence which hybridizes to SEQ ID NO: 17.

31. An isolated DNA molecule of at least about 20 base pairs which is selected from the group consisting of a sequence between about nucleotides -328 to -2 of Figure 11 (SEQ ID NO: 18) and a sequence which hybridizes to a sequence between about nucleotides -328 to -2 of Figure 11 (SEQ ID NO: 18).

32. A method of producing a homologously recombinant

cell wherein the expression of the DNase I gene is altered, comprising the steps of:

(a) transfecting a cell containing the DNase I gene with the DNA construct of one of Claims 21-29; and

(b) maintaining the transfected cell under conditions appropriate for homologous recombination.

33. A homologously recombinant cell produced by the method of Claim 32.

34. A homologously recombinant cell which expresses DNase I comprising an exogenous regulatory region, an exogenous exon, and an exogenous unpaired splice-donor site operatively linked to an endogenous splice acceptor site of the DNase I gene.

35. The homologously recombinant cell of Claim 34 wherein the exogenous regulatory region, the exogenous exon, and the exogenous unpaired splice-donor site are operatively linked to the endogenous splice acceptor site of the second exon of the DNase I gene.

36. A method for producing DNase I comprising the steps of maintaining the homologously recombinant cell of Claim 34 or 35 under conditions appropriate for the production of DNase I.

37. A method for producing DNase I wherein the expression of the DNase I gene is altered, comprising the steps of:

(a) transfecting a cell containing the DNase I gene with the DNA construct of one of Claims 21-29; and

(b) maintaining the transfected cell under conditions

appropriate for homologous recombination; and

(c) maintaining the homologously recombinant cell produced in step (b) under conditions appropriate for the production of DNase I.

5           38. A DNase I produced by the method of Claim 37..

39. A pharmaceutical composition comprising the DNase I of Claim 38.

10           40. A method of providing DNase I to a mammal in need thereof comprising administering homologously recombinant cells of Claim 34 or 35 in sufficient number to produce a therapeutically effective amount of DNase I in the mammal.

15           41. A DNA construct capable of altering the expression of a gene encoding  $\beta$ -interferon when inserted by homologous recombination into chromosomal DNA of a cell, said construct comprising:

- 20           (a) a targeting sequence comprising DNA which hybridizes to genomic DNA within or upstream of the  $\beta$ -interferon gene;
- (b) a regulatory sequence;
- (c) an exon;
- (d) a splice-donor site;
- (e) an intron; and
- (f) a splice-acceptor site

25           42. The DNA construct of claim 41 wherein the regulatory sequence comprises a promoter.

43. The DNA construct of Claim 42 further comprising a selectable marker gene.

44. The DNA construct of Claim 42 further comprising an amplifiable marker gene.

45. The DNA construct of Claim 41 further comprising a second targeting sequence comprising DNA which hybridizes to genomic DNA within or upstream of the  $\beta$ -interferon gene.

46. The DNA construct of Claim 41 wherein the targeting sequence is selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24 or fragments thereof or a sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24 or fragments thereof.

47. The DNA construct of Claim 46 wherein the targeting sequence is a fragment of SEQ ID NO: 23 and is at least about 20 base pairs.

48. The DNA construct of Claim 46 wherein the targeting sequence is a fragment of SEQ ID NO: 24 and is at least about 20 base pairs.

49. An isolated DNA molecule of at least about 20 base pairs selected from the group consisting of SEQ ID NO: 23, a fragment thereof, and a sequence which hybridizes to SEQ ID NO: 23.

50. A method of producing a homologously recombinant cell wherein the expression of the  $\beta$ -interferon gene is altered, comprising the steps of:

- (a) transfecting a cell containing the  $\beta$ -interferon gene with the DNA construct of one of Claims 41-48; and
- (b) maintaining the transfected cell under conditions



appropriate for homologous recombination.

51. A homologously recombinant cell produced by the method of Claim 50.

52. A homologously recombinant cell which expresses  $\beta$ -interferon comprising an exogenous regulatory region, an exogenous exon, an exogenous splice-donor site, and exogenous intron, and an exogenous splice acceptor site operatively linked to the  $\beta$ -interferon gene.

53. A method for producing  $\beta$ -interferon comprising the steps of maintaining the homologously recombinant cell of Claim 52 under conditions appropriate for the production of  $\beta$ -interferon.

54. A method for producing  $\beta$ -interferon wherein the expression of the  $\beta$ -interferon gene is altered, comprising the steps of:

(a) transfecting a cell containing the  $\beta$ -interferon gene with the DNA construct of one of Claims 41-48; and  
(b) maintaining the transfected cell under conditions appropriate for homologous recombination; and

(c) maintaining the homologously recombinant cell produced in step (b) under conditions appropriate for the production of  $\beta$ -interferon.

55. A  $\beta$ -interferon produced by the method of Claim 54.

56. A pharmaceutical composition comprising the  $\beta$ -interferon of Claim 55.

57. A method of providing  $\beta$ -interferon to a mammal in need thereof comprising administering homologously recombinant cells of Claim 52 in sufficient number to produce a therapeutically effective amount of  $\beta$ -interferon in the mammal.

5

## TRANSKARYOTIC PRODUCTION AND DELIVERY OF DNASE

### Abstract of the Disclosure

5 The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and  $\beta$ -interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or  $\beta$ -interferon. The invention further relates to a methods of producing pharmaceutically useful preparations containing thrombopoietin, DNase I, or  $\beta$ -interferon from homologously recombinant cells and methods of gene therapy comprising administering homologously recombinant cells producing thrombopoietin, DNase I, or  $\beta$ -interferon to a patient for therapeutic purposes.

277589.B11

# Activation of the Human Thrombopoietin Gene by Homologous Recombination: Embodiment 1




FIG. 1

Activation of the Human Thrombopoietin Gene by Homologous Recombination: Embodiment 2




FIG. 2

# HUMAN THROMBOPOIETIN

5' Flanking sequence and Exons  
1, 2 and 3




FIG. 3

XbaI (-6372)

-6373 TCTAGAGTCAGGATGGCACTGAAGGTCTCTGGGGAAGGGACGATGATGAGAGCCCGTCAGAA

-6311 ACCCTCCCCCTTTCTGGGTGATAGAGAAGACTCAGAACTTCACGCCCCGGGGCTCTTTGCT

Apal (-6233)

-6249 CCCTACCTGCAGCCAGGGCCCGGTGCGATGAGAGCCCCCAGACCTCCCTGAAGGGTGAGTGA

-6187 GTGTCACAAGTGCCACATGCAGCTGTTCTGCCCTAAGGAGCCGCAGAGACAACCGAGGCACT

-6125 GCCCGCCACACCCACAGACCTGGAGCAGAGAGACAAGAAGGCCCTACGCTCAGACACTGTG

-6063 CAGGCTAGGCCAATTAGGATGCCCAGGCAGGGCTTATGAAAAGGAACATGGAAAGGAACCT

HindIII (-5985)

-6001 CCAGGGTGCCCTAGGAAGCTTAAGAAAGAACGCTGGAGCCAGATGCTTGGGTTCGAATCCTG

-5939 GCTGCACCACTTCCTAGCTGTGTGACCTTGAATCAAATCACATTATCCTACTGAGCCTCAGT

-5877 TCCCCCTTCTGTAAAATGGGCATCATAATGTCAGTGCCTTCCTCCCACTGGGCTGTGGTGAG

-5815 GACCACGGGAGGCAATGCAGAGCATGCTCTCGGCACAGTGCCCAGACTGGGCAAGTGCTATA

-5753 AATGGCATCATCTCACCAGGCCTATCTTGGGTGGRGTGGGCTGCAGGGTGCTCAAACAGGAC

BamHI (-5667)

-5691 ACTGCCATTGGAGTCTGAGAAGCGGATCCTGGTAGGGCGGTCCAGCCTGGGAATGAGAGGTC

-5629 GGGTGAGGCCGGACTGAGCCAAAAGCAGCCCCTCCCAGCTCTCCCAGTTTCCCTCCSGGCCC

-5567 CGGCAGCGTGACCCCTCCTTGCTCCTTCCCCCTTCTCACCGCCTGTAGGAGATAGAGAAGCG

-5505 GAGGCTAGAGCGCCAGCAGCGAGACTCGGCTCGTGCCACCGCCTGCGACCTCGGCCCTGTCA

-5443 GCAGCGCCACGAAGTCTGGGACGGGAGGAAGATGGCCTGAGCACTGTCAAACGCCGCTTTGG

-5381 TGGCCCAGCCTCAACCACAACCCCGCTGTTCGCCAGCCCCCTACCCGTGTGGCCGTCACCAC

Apal (-5318)

-5319 GGGCCCGCTCCTCAGCGCCTGGCTCCCCGCGGTGCTATAACTGCGATGCTCCGGGTCCCGC

-5257 GGATACACGAAGGACAGGCCGCTCGGCTGCCGCTCCGAACTGCTGCGCTCTGCGGSGGGGGG

-5195 GTAAGAACACGGGCTTCAGCTGGCCATGGGAAAGGCCAGTCCGACGCCCCATCCAAGTGGCC

**FIG. 4A**



-5133 CGGGACCTAGTATCGTGGCCCTGCCTCCCTCCCCGCAGCGGAGCAAGACTTACCCTGGGGGC  
 -5071 AGGTCTGGCAGCAGTGTCCCGGCAGCTGGCGCGGCTGCCCCACAGGCCGGGGTTGGGCACTCT  
 -5009 GGTTTGATGTTCTTGCAGCTGACCCTGCCAGGCCCTGGTACGGCGACCCCACTGAGGCTGC  
 -4947 TCCCGGAAAAGGCGGGAAACCCAAGTGAGTGCAAGATGCCAACTGATGAGACCCCCCAGGC  
 -4885 AAGGATGTCCCGCAGAGTCAGCCAGCTCTGCCACTTACAAGCTGCGTGACCCTAGACAAGCT  
 -4823 ACTTCATCTCTCTGGGCCTCAAGGTCCCTGTCTGGAAAATGGGGATAATAATACTCTCTATC  
 -4761 TAGCAAGGCTGCCATGAGAGTTAGATGAGCAGGGAACGAAACGGAGTTGGCACAGAGCCTCA  
 -4699 CACAGAGTGGGCGATCAGTAACAGCACCTAAGAATTGGAGGGGCTGATTCCCCTTCCTCCAC  
 -4637 CAGAAAAATATCCCCAACATCTGCCGACTGGGCTCCTTCTCAGCAGCTCCGAGTCCACTCCG  
 -4575 ACGCCCGCGCGACCCGGCCGTCCCCACCCGCCAGCCCGGGCCGGCCGCGGGGTGCACTCACC  
 -4513 GCCTCGCAGGCCACAGCACGCAGCGCATCACCCCGAATGGCTCCCCTAGGTCCGGGTGCCAC  
 -4451 GTCTCGTCCAAGGCATAGACCTTCCCGCCGAAGTGCAGCCTGCGGGACGGGCTTGGCTGGAG  
 -4389 GCGCTGCCCAGCTCGCGCCGTGTGCCGCCCCGGGGGCTGCCCGCGGGTCCCGGGTCCCAGGC  
 -4327 ACCGCGCCCTTCTGCCCCCGCCACCCTCCGGGCGCGCCGCGCGCCGAGCCACCTGCGCCC  
 -4265 CGCGCCCCCTCCTCCGGCTCGGCTGACTCGCCCCGAGCCCGACTCCCCGCCCCGCTCCCCCGG  
 -4203 GCGCCACCTACCCTGCTGCCCCGAACGGGCAGCGGCTCCTTCTCAGAACGGATGGGCAGCAC  
 -4141 GGGGGCTCTCGGGCCGCGCGGGGCGGGAGCCGAGCAGCAGCAGCCCGAGGAGCAGCAGCGGG  
 -4079 GCCGGCGGGGCCGGGAGGGCHCGGCATGACGCGAACGGGACAGCTGGGGAGGAGGGAGGGAG  
 -4017 GAGGGCGCGGGAGCGGGCGGAGGGAGGGAGGCGGGAGTGCGGAGGGCGGAGGGCCGGGCCGG  
 -3955 GGGCGGTGCGGCGGGAGGGGGCCGGGGCCGGGGCCGGGGCCGGGGCAGTGCCCCGCGAGGGGC

SfiI (-4079)

**FIG. 4B**

NotI (-3885)

-3893 TCGTCGGGCGGCGCAGAGTCGGCGCCGGGCGGGCGGGGAGGAGCGGCCGGGAGGAG  
-3831 CGCGGGCGGGCGGGCGCTGACCGGGCCGTACGCGGCTCTACTGCCCCGGGCGCCGGCTCCG  
-3769 GCCCGTTTTATGCCCCGCGCCCGACGCCCCGGCCGGGGGCGCTCCTCCTCAGCAAACGGGGCG  
-3707 GCGGCGGCGGCTCGGCGAGGGGCGGCTGAGCCCGGGGGGTCCGACCCAGCAGCAGCGGCCCG  
-3645 GATCGCGGGTGGGGGAGGGGAGGGAGGGCTGGGACCGGGCAGGGGAGGAGGGAGGGGCGGGA  
-3583 GGGGAAGGGGAGCGGGGGAGGGGGAGGGGAGGGACCAGGGGGCGCGAAGAGGGGGAGGAGA  
-3521 GGCGGCCCCGAGCCCCCGCTGCTGGCGGCCACAGGGCGGCTGGACCAGGAGGTCCGTGTCCA  
-3459 GCCCAGGAAGGGAGCCTCAGGCTAGGGAGGGGCAGAGGCTTACCTGAGGCCTGGACCGCTCT  
-3397 GTGAGCGAGGCCCGGTTCCGCCCCGAAGGATAAACTTGTCTTTAAAGATACACGTACAGGAAA

Apal (-3307)

-3335 GGTCCATCAGCCGATCTCCCCCTGCCTGGGCCCACAGCGCCCCCAACCCTCACCACCCTC  
-3273 TCTCACTGCCTAGCCTGCCTCCCTACCTTCTCTCTGAGGTGCTCCTCCTTCTTGTGTTACC  
-3211 CAGRACAGGGACCTAGCCAGAAACCGGCAGCATTCCCCCCTTCTGTGGAGTGACAGTATCTCC  
-3149 CTCTCATTGTAACTTATCCTCAGGCGCATTCGACAGTCCCCTCTTGCTTTCTCACCCTTCTC  
-3087 CTTCACCCAAGGGACCCTCTGCCTCTCCAGCCCACTCCCAGCCTCCTTTCTCTTGGTTCCCT  
-3025 GGTCATGCCTGCCTCCCTGTCTCCTGTCTCTCCCTCCCACACACACCCACTATCCTCCCAGC  
-2963 TATCCCAGCACCCCTCCTTCCTAATCTTGGGAGACATCTCGTCTGGCTGGACGGGAAAATTCC  
-2901 AGGATCTAGGCCACACTTCTCAGCAGACATGCCCATCCTTGGGGAGGAGGAACAGGAGAGAG  
-2839 CCTGAGGAAGTTCTGGGGGACAGGGGGATGATGGGATCAAGGTCAGGCCAGGAAGCCCCTGA  
-2777 GGACAGAGACTGTGGGGAGACTTGGGACTGGGAAGAAAGCAAAGGAGCTAGAGCCAGGGCCA  
-2715 AAGGAAAAGGGGGGCCAGCAGGGWGGTATTTGCGGGGGAGGTCCAGCAGCTGTCTTTCCTAA

FIG. 4C

-2653 GACAGGGACACATGGGCCTGGTTATTCTCTTGTACATGTGGAACGGTAGGAGATGGAAGA

Apal (-2568)

-2591 CGGAGACAGAACAAGCAAAGGAGGGCCCTGGGCACAGAGGTCTGTGTGTGTAGCCATCTAAG

-2529 CCACTGGACCCCAGCAGACGAGCACCTAAGCTCAGGCTTAACCAGTGCACGTGTGCGCACAT

-2467 ACTGTGCCCCGCACCTGACGTCCACTCAACCCGTCCAAACCCCTTTCCCCATAACACCAACCC

-2405 ATAACAGGAGATTTCTCTCATGTGGGCAATATCCGTGTTCCCACTTCGAAAGGGGGAATGAC

-2343 AAGATAGGACTCCCTAGGGGATTACAGAAAGAAAAGCAGGAAAGCAAGCATCCTGTTGGATT

-2281 TCAGCAGCAGGTATGATGTCCAGGGAAAAGAAATTTGGATAGCCAGGGAGTGAAAACCCAC

-2219 CAATCTTAAACAAGACCTCTGTGCTTCTTCCCCAGCAACACAAATGTCCTGCCAGATTCTC

-2157 CTGGAAAAAACTTCTGCTCCTGTCCCCCTCCAGGTCCAGGTTGCCCATGTCCAGGAAAAGAT

BamHI (-2094)

-2095 GGATCCCCCTCATCCAAATCTTCTCCGTGTGTGCTGTGGGTGGAGTGAGTRGWARCCCTGGT

-2033 CCAGGCAGGGVGCTCCAGGGAAGAGCAAGGCGTCACTTCCGGGSGCCTTCACCAGTGTCTGG

-1971 TGGCTCCCTTCTCTGATTGGGCAGAAGTGGCCCAGGCAGAGCGTATGACCTGCTGCTGTGGA

-1909 GGGGCTGTGCCCCACCGCCACATG

FIG. 4D

-1885 TCTTCCTACCCATCTGCTCCCCAGAGGGCTGCCTGCTGTGCACTTGGGTCTGGAGCCCTTC

-1823 TCCACCCGGTGAGTGGCCAGCAGGGTGTGGGGTTATGTGAGGGTAGAAAGGACAGCAAAGAG

-1761 AAATGGGCTCCCAGCTGGGGGAGGGGCAGGCAAACTGGAACCTACAGGCACTGACCTTTGTC

-1699 GAGAAGAGTGTAGCCTTCCCAGAATGGGAGGAGCAGGGCAGAGCAGGGGTAGGGGGTGGGGT

-1637 GCTGKTTTCCTGAGGGACTGATCACTTACTTGGTGGAATACAGCACAGCCCTGGCTGGCCCT

-1575 AAGGAAAGGGGACATGAGCCCAGGGAGAAAATAAGAGAGGGAGCTGCACTTAGGGCTTAGCA

-1513 AACACAGTAGTAAGATGGACACAGCCCCAATCCCCATTCTTAGCTGGTCATTCCTCGTTAGC

-1451 TTAAGGTTCTGAATCTGGTGCTGGGGAAGCTGGGCCAGGCAAGCCAGGGCGCAAGGAGAGGG

ApaI (-1377)

-1389 TAATGGGAGGAGGGCCCACTCATGTTGACAGACCTACAGGAAATCCCAATATTGAATCAGGT

-1327 GCAAGCCTCTTTGCACAACTTGTGAAAGGAGGAGGAAGCCATGTGGGGGGTCTGTGAAGGA

-1265 ACCGGAAGGGGTCTGCCAAGGGGGCAGGGAGGCAGGTGTGAGCTATGAGACAGATATGTTA

-1203 GTGGGCGCCTAAGACAAGGTAAGCCCCTAAGGTGGGCATCACCCAGCAGGTGCCCGTTCCTG

-1141 GGCAGCTGGTTTTAGGAAGGAAGTCCCAGAACTGTTAGCCCATCTCTTGGCCTCAGATAATG

-1079 GAGTATTTACAGGACTTGGAGTCCAGAGAAAAGCTCCAGTGGCTTTATGTGTGGGGGTAGATA

-1017 GGGAAAGAATAGAGGTAAATTTCTCCCATACCGCCTTTTAATCCTGACCTCTAGTGGTCCCA

-955 GTTACAGCTTTGTGCAGTTCCCCTCCCCAGCCCCACTCCCCACCGCAGAAGTTACCCCTCAA

-893 CATATTGCGCCCGTTTGCCAGTTCCTCACCCAGGCCCTGCATCCCATTTTCCACTCTCTTCT

-831 CCAGGCTGAAGCCACAATACTTTCTTCTCTATCCCCATCCCAGATTTTCTCTGACCTAACA


-769 ACCAAGGTTGCTCAGAATTTAAGGCTAATTAAGATATGTGTGTATACATATCATGTCCTGCT

-707 GCTCTCAGCAGGGGTAGGTGGCACCAAATCCATGTCCGATTCACTGAGGAGTCCTGACAAAA

**FIG. 5A**



Activation of the Human Thrombopoietin Gene by Homologous Recombination with pRTPO1







# Activation of the Human Thrombopoietin Gene by Homologous Recombination with pRTPO3




FIG. 8

Restriction Map of the DNase I 5' Flanking  
Region Including Exons 1 and 2




FIG. 9

[illegible]

7

12 2  
 13 2  
 14 2  
 15 2  
 16 2  
 17 2  
 18 2  
 19 2  
 20 2  
 21 2  
 22 2  
 23 2  
 24 2  
 25 2  
 26 2  
 27 2  
 28 2  
 29 2  
 30 2  
 31 2  
 32 2  
 33 2  
 34 2  
 35 2  
 36 2  
 37 2  
 38 2  
 39 2  
 40 2  
 41 2  
 42 2  
 43 2  
 44 2  
 45 2  
 46 2  
 47 2  
 48 2  
 49 2  
 50 2  
 51 2  
 52 2  
 53 2  
 54 2  
 55 2  
 56 2  
 57 2  
 58 2  
 59 2  
 60 2  
 61 2  
 62 2  
 63 2  
 64 2  
 65 2  
 66 2  
 67 2  
 68 2  
 69 2  
 70 2  
 71 2  
 72 2  
 73 2  
 74 2  
 75 2  
 76 2  
 77 2  
 78 2  
 79 2  
 80 2  
 81 2  
 82 2  
 83 2  
 84 2  
 85 2  
 86 2  
 87 2  
 88 2  
 89 2  
 90 2  
 91 2  
 92 2  
 93 2  
 94 2  
 95 2  
 96 2  
 97 2  
 98 2  
 99 2  
 100 2  
 101 2  
 102 2  
 103 2  
 104 2  
 105 2  
 106 2  
 107 2  
 108 2  
 109 2  
 110 2  
 111 2  
 112 2  
 113 2  
 114 2  
 115 2  
 116 2  
 117 2  
 118 2  
 119 2  
 120 2  
 121 2  
 122 2  
 123 2  
 124 2  
 125 2  
 126 2  
 127 2  
 128 2  
 129 2  
 130 2  
 131 2  
 132 2  
 133 2  
 134 2  
 135 2  
 136 2  
 137 2  
 138 2  
 139 2  
 140 2  
 141 2  
 142 2  
 143 2  
 144 2  
 145 2  
 146 2  
 147 2  
 148 2  
 149 2  
 150 2  
 151 2  
 152 2  
 153 2  
 154 2  
 155 2  
 156 2  
 157 2  
 158 2  
 159 2  
 160 2  
 161 2  
 162 2  
 163 2  
 164 2  
 165 2  
 166 2  
 167 2  
 168 2  
 169 2  
 170 2  
 171 2  
 172 2  
 173 2  
 174 2  
 175 2  
 176 2  
 177 2  
 178 2  
 179 2  
 180 2  
 181 2  
 182 2  
 183 2  
 184 2  
 185 2  
 186 2  
 187 2  
 188 2  
 189 2  
 190 2  
 191 2  
 192 2  
 193 2  
 194 2  
 195 2  
 196 2  
 197 2  
 198 2  
 199 2  
 200 2  
 201 2  
 202 2  
 203 2  
 204 2  
 205 2  
 206 2  
 207 2  
 208 2  
 209 2  
 210 2  
 211 2  
 212 2  
 213 2  
 214 2  
 215 2  
 216 2  
 217 2  
 218 2  
 219 2  
 220 2  
 221 2  
 222 2  
 223 2  
 224 2  
 225 2  
 226 2  
 227 2  
 228 2  
 229 2  
 230 2  
 231 2  
 232 2  
 233 2  
 234 2  
 235 2  
 236 2  
 237 2  
 238 2  
 239 2  
 240 2  
 241 2  
 242 2  
 243 2  
 244 2  
 245 2  
 246 2  
 247 2  
 248 2  
 249 2  
 250 2  
 251 2  
 252 2  
 253 2  
 254 2  
 255 2  
 256 2  
 257 2  
 258 2  
 259 2  
 260 2  
 261 2  
 262 2  
 263 2  
 264 2  
 265 2  
 266 2  
 267 2  
 268 2  
 269 2  
 270 2  
 271 2  
 272 2  
 273 2  
 274 2  
 275 2  
 276 2  
 277 2  
 278 2  
 279 2  
 280 2  
 281 2  
 282 2  
 283 2  
 284 2  
 285 2  
 286 2  
 287 2  
 288 2  
 289 2  
 290 2  
 291 2  
 292 2  
 293 2  
 294 2  
 295 2  
 296 2  
 297 2  
 298 2  
 299 2  
 300 2  
 301 2  
 302 2  
 303 2  
 304 2  
 305 2  
 306 2  
 307 2  
 308 2  
 309 2  
 310 2  
 311 2  
 312 2  
 313 2  
 314 2  
 315 2  
 316 2  
 317 2  
 318 2  
 319 2  
 320 2  
 321 2  
 322 2  
 323 2  
 324 2  
 325 2  
 326 2  
 327 2  
 328 2  
 329 2  
 330 2  
 331 2  
 332 2  
 333 2  
 334 2  
 335 2  
 336 2  
 337 2  
 338 2  
 339 2  
 340 2  
 341 2  
 342 2  
 343 2  
 344 2  
 345 2  
 346 2  
 347 2  
 348 2  
 349 2  
 350 2  
 351 2  
 352 2  
 353 2  
 354 2  
 355 2  
 356 2  
 357 2  
 358 2  
 359 2  
 360 2  
 361 2  
 362 2  
 363 2  
 364 2  
 365 2  
 366 2  
 367 2  
 368 2  
 369 2  
 370 2  
 371 2  
 372 2  
 373 2  
 374 2  
 375 2  
 376 2  
 377 2  
 378 2  
 379 2  
 380 2  
 381 2  
 382 2  
 383 2  
 384 2  
 385 2  
 386 2  
 387 2  
 388 2  
 389 2  
 390 2  
 391 2  
 392 2  
 393 2  
 394 2  
 395 2  
 396 2  
 397 2  
 398 2  
 399 2  
 400 2  
 401 2  
 402 2  
 403 2  
 404 2  
 405 2  
 406 2  
 407 2  
 408 2  
 409 2  
 410 2  
 411 2  
 412 2  
 413 2  
 414 2  
 415 2  
 416 2  
 417 2  
 418 2  
 419 2  
 420 2  
 421 2  
 422 2  
 423 2  
 424 2  
 425 2  
 426 2  
 427 2  
 428 2  
 429 2

7

Apal (-3353)  
 -3360 CCAGACGGGCCCCATGTCAGACCAGGCTCCTCCAGGGCTGTCGCTGCCCTACCAAAGCCCGTC  
 -3296 CTGAGGGCAGCCACACAGCAGGCAGCACTCGCCATTTGTACAAGCGAGGCCCAAGTTCCAGCCT

**FIG. 10A**

-3232 TCCTTCTGGCAGGTAGAGGAAGCAGGGGCACTATGCCTGGGAGTTCTGAAAGCAGATGGGGCA

Espl (-3109)

-3168 GCATTTGGTCAAGAGCCAGGAGGGGATGACAGACCAGAGGGGAACCCTCGTCCCACGTGCTGAG

-3104 CACACGTAGGGGGTTGGGCACTTGCTCTGTGAGCTATAATTGGTGTCCCTGTGCCCCGCCGGAA

-3040 GCTGCACCAGGCAGTTTCTTGGTGGAGGACAGTGGCCGCCCTCTAGCTTTACTCCCTTCCCCGT

-2976 GATGGGTGCTGTCAGATGTGTGTCCAGGAAAGGCAAACACCAAAGGCAGAGGACTAGTCCCTA

-2912 CACCGAATACTCCGGTGGCCTTGCTTGGGGGCTGGGTTTTGACGTGCTGGAGGCTGTCCTAGAC

-2848 TTAGAGATTAAAAACAGGGAAGAACCATTGCTGAAACCTTTGGAAAAGCCTGCAATGGCCTCTG

-2784 GCAGCCTGAGGAGTGGTGGTGTTCATCTGGTAGACGCCGTCTCAATAGGAGGGACAGATGAG

-2720 TGCACCAGTGCTGCCAGCCAGAGGCGTCTGTTGGCGTGTCTTTATGGAATGGGGTGCCAGTCTT

-2656 GTGGAGGGTGGTTTACCTTCCTGTTTCTAGTCCCCACTGGGCCTGCCTTCTGCTTCATGCCAGC

-2592 TGGCCAGACCGAGCACTTTCCTGACTTTCGACCTTGGCCCCCTGCTGACTCTTGCCGTTGAGGCC

-2528 TCCTGCAGACCCCATTTGTATTCAATTCCTGCAGTTCTCATACCTGAATCCCGCCTGGACTTCT

-2464 GCCAACCGTTCCAGGCCCTCCTCCCAGGGGGACCACAGATGCTACGTGCAGGGCTGTCCTTGGA

-2400 GGGCCAGCACAGCCCCCTTCCAAGTGGGCAAGACCCAGGGGTGGCTCAAAGATAGCTGTGCCCT

-2336 AGCCCTGGAACCTCTGAATGTTGATTTTGTAGCAAAAAGGACTTGCAGATGTGAGTAAAGGC

-2272 TGTGAGATAAGGACATCCTCCCTGCTCTCTGGGAGGACCCCAAATGCAGGTGCACAGATCTTA

-2208 AGAAGAAGAGGCAGAGACTGGGGTGATGCAGCCACAATAAGGAAAGCCAAGGATTGCTGGCAG

-2144 CCTGCAGAACTGGAGGGCAAGGAGCATCCCCCAACCGCCCGGAGCCTCCAGGAGGCGCAAGGT

BamHI (-2032)

-2080 CCTACTGACTCCCTGACTTCAGACGTCCAGTCTCCGGAATTTTGAGAGGATCCATTTCTGTTAT

-2016 TTTAAGCAACCAAACCTTGTGGTAGTTTCACCAGTCTCAGGAAATGAATACGAATGGAAAGTCAA

FIG. 10B

-1952 AGATTCCAAGAAATGAGTGGCGGGGTGCGGTGGCTCACACTTGTAATCCCAGCATTTGCGGGAA

-1888 GATTGCTTGGGCTCAGGACTTGGAGACCTTGTGTCTGTGAGAACTTAAAAAATAGGCTGGGTG

-1824 CGATCGTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCGGATCACAAGGTCACGA

-1760 GTTTGAGACCAGTGTGACCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCG

-1696 GGTGTGGTGGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGAAGAATTGCTTGAA

-1632 CCCAGGAAGCAGAGGTTGCAGTGAGCCGAGATAGTATTACTGCACTCCAGGCTGGGCAGCAGAG

SphI (-1509)

-1568 CAAGATTCCGCCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTGAGCATGGTAGCATGC

-1504 ACCTGTGGTCCTCGTACGCCGGAGGATTGCCTGAAGCCAGGAGTTCAAGACCAGTCTGGACAAA

-1440 AGAGCAAGACCCCATCTCTACCAAAAAAATTTAAAAATTAGCCAGGCATGGTGCCGTACCCATA

-1376 GTCTTAGCTACTCAGGAGGCTGAGGAGGGAGGATTATCTGAGCCTGGCGGTTGAGGCTATAATG

-1312 AGCCATGATTTGGCCACTGCACTCCAGCCTTGGCAACACAGTGTGAGACCCTGTCTCAAAAACA

-1248 ATAAAAACCCAAAACAAAAGAACCAAGAAATTACTGGACCTGAGCCTGGCCTTTAGCTGCTGCC

BamHI (-1162)

-1184 CTGCCCTKTGACTGGTCACTCGGATCCCTGGGCCTAAACACACAGCCTATTGTCTACCTCAAGA

-1120 AGGCTCCCCACTGCTTGGCTGGCAATTGGGGTGGCTTTGCAGGCCCCACCTGTCCTGGCCCCAC

-1056 GGCGCTGGTGCTGCAGGCCCCCACCCTGCTTGTTCGAGCTCCCCAGCCTCCTGCAGAGTTGC

-992 CTGCACCTGATGGCGATGAATCAGGAAGGCAGGCGTGTCTTGGGCCACAGAGCAGTCATGCTGT

-928 CAGCCACCAGGGGGCTCCATTTGCAACTTTGGATGTGGCTTTGGCCTCTTTGTCCAAAGTGACC

ApaI (-860)

-864 TTGGGGCCCCCAGACAAGAGACAGGGAGACTGGAGCCCAGCCCCACCCTCCCGCACATACCTGG

-800 CCCATCCCTGCCCTATCCTGGAAGATGGGGGCCACCACACGTRCAAGGGACACGGGATAGGAAC

-736 CTTTGGCCTTGTTATCAGACATTTTAAAACTAAGTGCAAACGTGATTATCAGGTGCAGTTTTTA

**FIG. 10C**

-672 CAGCAGCAAGAAACCTGTGCTTACAGAAAGAAACACGTGCTAGCAACCCACCTATGCGGAAAGCC  
-607 ACACAGAGCCATTGTTTTCTGCACTCTCAGGTGACGGCTCACATTTGCCCCAGGGAAGGTCACAG  
BamHI (-498)  
-542 CTGCCTGAACTTTTAAAACTCCCAGACACGCACTGCCTGTGCAGGATCCGGAGCCCAGCAGCACT  
-477 GCCAGGG

**FIG. 10D**

CAP site (-469)

-470 CCTTGAAGTGCTTCTTCAGAGACCTTTCTTCATAGACTACTTTTTTTCTTTAAGCAGCAAA

-408 AGGAGAAAATTGTCATCAAAGGATATTCAGATTCTTGACAGCATTCCTCGTCATCTCTGAGG

-346 ACATCACCATCATCTCAGGTGAGCACCAGGTGGAGTGCCTCTGGGTGACTGGCCGGTTTGGA

-284 GCAGGGAGGGAGGCTTAGAGTCTCATCCTCCAGCAGCGAGTGAGGCGGAGGCTCCAGCGTCC

SmaI (-220)

-222 TCCCGGGCGGGTTTTCTGGTGGATGGAGGAGTGACTCGGGGTCTCTACGTGGTGCCAGCTG

-160 TTTGGCTTTCTGGACGTTGTAGGAAAGGGTTTTCCCCCGCCTGCGTCCCCCTGACCTTGAGCT

-98 CCACCAGCCCCCTGCCAGCTGGGCTCCAGAAGGCTGGAGTGCTGTGGCAGGGATGACGTCTCA

AUG (1)

-36 CTTCTGTTATGTCTCTGTGCCCTGTGCTCTCCAGG ATG AGG GGC ATG AAG CTG

19 CTG GGG GCG CTG CTG GCA CTG GCG GCC CTA CTG CAG GGG GCC GTG

64 TCC CTG AAG ATC GCA GCC TTC AAC ATC CAG ACA TTT GGG GAG ACC

109 AAG ATG TCC AAT GCC ACC CTC GTC AGC TAC ATT GTG CAG ATC CTG

154 AGC CGC TAT GAC ATC GCC CTG GTC CAG GAG GTC AGA GAC AGC CAC

199 CTG ACT GCC GTG GGG AAG CTG CTG GAC AAC CTC AAT CAG GAT GCA

244 CCA GAC ACC TAT CAC TAC GTG GTC AGT GAG CCA CTG GGA CCG AAC

289 AGC TAT AAG GAG CGC TAC CTG TTC GTG TAC AGG CCT GAC CAG GTG

334 TCT GCG G

FIG. 11

Activation of the Human DNase I Gene by Homologous Recombination with pDNase1





FIG. 12



# Human $\beta$ -Interferon

5' Flanking sequence,  
coding sequence and 3'  
untranslated sequence



600

**FIG. 13**

-8711 AGCTTCTGCTTTAGGAAAGTAGAAAAATAAGAGCAAATTAAATCCAAGGTAAGTAAAAAAAAAAAA  
 -8646 AAAAAAAAAAAGAAATAAAAATTAGAGCAGAAATCAATAAAATTGAAGACAGTAAATCAATAAA  
 -8581 GAAATCAACATAAAAAGTCTGGTTCCTTGAAAAGATATATAAAATTGATAAGCATCTACCTAGGA  
 -8516 TAATTAAGGAAAAAGACAGAGGACACAGATTACTAATATCAAACATAAAAGCGGGAACATCACT  
 -8451 GCAAATTTTATAGGCATTGAAAGCGTAATAAAAGAATACTATAAACTATTCTATAACTACAAATT  
 -8386 TGATAAGTAAATAGAATGAACCAATTCCTTGAAAGACATAATCTGAAAAATGTAAAAGAAGAAA  
 -8321 TAAACAATCTGAATAGCCTATATCTATTAAATAAATTGAATCAGTAATTAATAACCTCTCAAAAC  
 EcoRI (-8223)  
 -8256 AGGAAGCACAATGCCCAGATGGGTTCAGTAGTGAATTCTATCAAATATTTAAAGAAAAAAAAAATT  
 -8191 GTATCAACTTTCTACAATCTCTTTCAGAAGACAGAAGCAGAGGGAATACTTCCTAAATCATTCAA  
 -8126 CTAGGCCAGCATTACCTTAATACCGGAAGTAGAAAATGACATTACAAGAAAAGAAAACAACAGAC  
 -8061 CAATATCTCTCATGAACAAAGATACAAACATTTTCAACAAAATATTAGCAAAAAGAATCCAAGAA  
 -7996 TGTATCAAAAAATATACACCACAACCAAGTAGAATTTATTCCAGATATGTAAGGGTGGTTCAACG  
 -7931 TTTGAAAATCAATTAACGTAATTTGTCCCATCAACAGGTTAAAGAAGAAAATCACATGGTCATAT  
 -7866 TGATAGACACAGAAAAGCATTGACAAAATTTAACACCCATTCATGATGCAATCTCTCAGTAAA  
 -7801 CTAGGAATAGAGGAAAACCTTCCTCAGCTTGAATGTACCTTCCTCTCAATTTTGCTATGAACCTGA  
 -7736 AACTCCTCTTAAAAAATAAAGTTTTTCATTTAAAAAGAAAACAAAAACATGGAGGAGCGTTGAT  
 -7671 GTATCTCATTTTAGACCAATCAGCTATGGATAGTTAGGCGACAGCACAGATAGCTGCTGTACTTC  
 -7606 TGTTTCTGGCAATGTTCCAGACTACATTTAAAAAATTTTAAATTATAGACTTGTAATGTTTC  
 -7541 AAGAAAAATATGAAAATGCTTTGCCGTGTTAATGCTACTCTTTTTTAAAAAAACTAAAGTTCAA  
 -7476 ACTTTATTTATATTTTATTAGTTTTTTAGCTACTGTTCTTTTTCTGTTCTGGGATCTCATTGAGA

**FIG. 14A**

-7411 ATGCCACATTACATATAATTCTCATGTCTCCTTGGGTTCCCTCTTAGTMTTGACAGTTCCTCAGAC  
 -7346 TTTTCTTATTTTTGATGACCTTGACAGTMTTGAGGAGTACTGGTTAGATATAGGGTAATGGTTTT  
 -7281 TAAAGTATATTTGTCATGATTTATACTGGGTAAGGGTTTGGGAGGAAGCCATGGGTAAGTACTGT  
 -7216 TCTCATCACATCATATCAAGTTATATAACCATCAATATTGCCACAGATGTTACTTAGCCTTTTAAT  
 -7151 ATTTCTCTAATTTAGTGTATATGCAATGATAGTTCTCTGATTTCTGAGATTGAGTTTCTCATGTG  
 -7086 TAATGATTATTTAGAGTTTCTCTTTCATCTGTTCAAATTTTGTCTAGTMTTATTTTTTACTGATT  
 -7021 TGTAAGACTTCTTTTTATAATCTGCATATTACAATTCTCTTACTGGGGGTGTTGCAAATATTTT  
 -6956 CTGTCATTCTATGGCCTGACTTTTCTTAATGGTTTTTTAATTTTAAAAATAAGTCTTAATATTCA  
 -6891 TGCAATCTAATTAACAATCTTTTCTTTGTGGTTAGGACTTTGAGTCATAAGAAATTTTTCTCTAC  
 -6826 ACTGAAGTCATGATGGCATGCTTCTATATTATTTTCTAAAAGATTTAAAGTTTTCCTTCTCCAT  
 -6761 TTAGACTTATAATTCACCTGGAATTTTTTTGTGTGTATGGTATGACATATGGGTTCCCTTTTATTT  
 -6696 TTTACATATAAATATATTTCCCTGTTTTTCTAAAAAGAAAAAGATCATCATTTTCCCATTTGTAA  
 -6631 AATGCCATATTTTTTTCATAGGTCACCTTACATATATCAATGGGTCTGTTTCTGAGCTCTACTCTA  
 -6566 TTTATCAGCCTCACTGTCTATCCCCACACATCTCATGCTTTGCTCTAAATCTTGATATTTAGTGG  
 -6501 AACATTCTTTCCCATTTTGTCTTACAAGAATATTTTGTATTGTCTTTTGGGCTTCTATATACA  
 -6436 TTTTAGAATGAGGTTGGCAAGTTAACAAACAGCTTTTTTGGGGTGAACATATTGACTACAAATTT  
 -6371 ATGTGAAAAGAAAGTATACCTTCACAATATTAAGTCTTTTAGTTCATGAATATAGTATGTCTCTC  
 -6306 CGTTTCTGCATTAACTTAGACATTCATTAATTTCTCTCACAATTTATAAGTTTATTTAGATCTTC  
 -6241 ATTCATTTAAATCTTCACTAACCTCTCATTTACAATTTGTAAGTTTTCTGGGTAAACAGTCTTGCA  
 -6176 CTTCTTTGCCTAGATTTATTTCCAAGTAGATTATTTTCATACATCGTCTATGGTGTCATTTTTAA

BglII (-6248)

FIG. 14B

-6111 AATGTAATTTTTCACCTTTTATTGCTAAAGAGAGATGACTGATTGTTAATATTGATCTTGTGCG

EcoRI (-6032)

-6046 TGGCGACCTTGCTGAATTCTAATCGTTTATCTATAAATTCTTTTGTATTTTGAATGTAAACAATT

-5981 AGATCATCTGCATATAATTTTAAAATCTGATAAGTCAACAAGAGATTGAAACAGGCTCTTCACA

-5916 AAGAAAATATCCAAATGGTCAATAAACATATGAAAAGATGCTGAAACTTGTTAATAATCAGAGAG

-5851 ATGCAAATTAAACTATAATGAAGTATTATTGTACAACAATAGAATGACTGAAATTAAAAAGACTG

-5786 ACAATATCAAAGTTGGCAAGAGTCTGATACAACTGGAACCTTCTCAAACACTGTTAGTAAGAATGT

-5721 AAATTGGTACAAACATTTGGGAAGTCATTACAATATTATCTGCTAAATCTGAACATATACATATT

-5656 CTATGAGCCAGTTACTTCATTCTAGGCATATACCCAAAAGAAGTATGTACTATTGTGCAGTAAAA

-5591 AATACAGACAAGGAATTTTCATAGGAGCATTAAATTATCATGGCAAATATTTTAAAAAATTATTAGT

-5526 AGTAGAAGGGATAAAACATTGTGGTATACTTCTAAATAGGGTAAACACATTAATGTAAATTAAT

-5461 AAACCTATACACACAAGATAGACGAATTTTCGCAGACATTCTGTTGAGGGTAAGAAGACCATTTATA

-5396 CAAAGCTCAAAAACAGACAGAATCTAGAGTGTTAAAAGACTGCATGGTAGTGACTTTGGGAGAAG

-5331 AAAGTAGTGACGAGAGAGAGAGAGAATAATGATTGCGAGGTGCTATAGTCTGAAGGTTTGTG

-5266 TCCCCCAAATTTTCACATGTATAAACCTAATCCCCAATGCAATCATTTTAAGAAGTGGGTCCTTTA

-5201 GTGGATAATTAGGTAATGGAACAAGAGCCCTAACAAATGGGATTGGTGCCTTATAAAAGAAGCCT

-5136 GAGCCTGAGGGACCTTGTTTCCCGCTTCTACCATATGAGAATGCAATGAGAAGGCACAAAGCAAA

-5071 GAGCAAGCCCTCATCAGACACTGAATCTGCTAGGGCCTTAGTCTTGGCTTTTCCAACCTCCAGAA

-5006 CTATAAAAAGAAATGCTTGTTGTTTAAAAGGCATTCAGTCTATCGGTGTTTGTAGAGCAGCCC

-4941 CAAGAGACTTAAGAGGGAACAAGAGGGCGATTTCTGTTGTGTTGATAATGTTTAGTTTGTGGTTA

-4876 CAAAGAGTGCAGACGTTTTTATTTTATAACAATTCATTGAGCTATATCTTAAGATGTATGCGTAA

**FIG. 14C**

EcoRI (-4759)

-4811 TTTTCTATGTATATTATTGTTTTATAAACTTTTTCTTAAAAGAGGAAATGGGAATTCTCCCTTTT  
-4746 ATGTATTAATCTCTTATGAAAGAGTTTGTTGGCTTCCCAAGATATTTCTGAAAGATTGCTTTTGG  
-4681 CTTCAATTTATGTTCTGCCACTGCTTATGCACCTCTCAATAACTCTTCATCTTGTATAATTTATCA  
-4616 TTCTTTGATAGGGACCCTCTTCCTTGAAAAATAATTGAAGATATAAGGAGGAGGAAGAGAAGACA  
-4551 ACTAAATGTTTATTTCTAGATACATAGTAGTCTGCATAGATAATTATATTCAAAGAGGAGGACA  
-4486 AATTGGCTCCTATCTCTGAAATTTATAGAAAAGCATTTCCACATTAAAGTGATTTCAAATGACTA  
-4421 GAAATGTCATTCAAGTTTTACTTTCTAAATGTCACCTCTGTCTCTCCAAACCTCATTAAACCACAAG  
-4356 GAACTGGTGCAGGGACTGGAAGTAGTTTTCTCATACAACGGAAAGTTAACGAGGGGAGGAAAGGA  
-4291 TGTGTGCAAAAATAACGTCCACAGAAGGGACAAATAACAAAGGGAAAGATGACAGGAAAGGGTTC  
-4226 GGGCACTAACCCTTACAATGCAGATACACACTGGGCTGGTCTAAGAAATAGGGTTCCTGGTAGA  
-4161 CAGAAGGTTAAATAAATTTTCCTGGTTATTCTGATACAACTCTAATAAAAGAAGAGAAATGAAGC  
-4096 TAAAACTTAAATGATGTATTTAAAAGGAAGAAATTTTAACCCATTTCATAGGTGAGCTTCTGCCA  
-4031 AGATTACTACTAATCCTCAGGAGAAGGGGTAGAGGAGAACTCCATAAAGGCAACTGGAAGTGGA  
-3966 GTATTAGGAAGCACCTCAAGAACACAATAGCAGGAAGTAGCTAGAGAACAAAGAGAAGAAAACCA  
-3901 GAAAAAATAATCCCTTTTTATTTTTCTGTTTCCATTCTTTGGCTCCATTTCCACAGCTATGGC  
-3836 CTTTATTTTCACCCTCCACAGCCATGAGAGCCTCTGGGCAGGAGTTCTCCTCGCCTCTCCCTGTT  
-3771 CCAATCACCTCTAACATTTCTGCCTATTGTTCTGCCCAGGGAAAAAACTCCAGTCTCTTCTCTGT  
-3706 CAAAGACCTCTTGAATTAAGTCCAAATGCTACACTCTGGCATTCAAGACTCGTAATACAGCTCAA  
-3641 CCTGACTTTTCCACCCTCAGCCTCCTTGATTCTTAAATGAAGCCTGTCCACAATTGAAGCTCCT  
-3576 TGTCTTTGCTCCTGCAAATTTGTTCAATCTCCTGGCTGTGTTTGTGCTGGTCTCTGTCTATCTAG

FIG. 14D

-3511 AGCTGTGGATATCATGGTATCTATTGTCTATCATGCTAGCCATGAACCACATGTGGCTGGTGAGC  
 -3446 ATTTTATATGGTACTAGTCTAAATTGACATCTACTGTGAGTGTA AAAATGTGCATTATGTTTTGA  
 -3381 AGACTGTACACAAAATTTAATTATCTCATGAATAATTTTAGATTGGTTATATGTTGAAATTATAA  
 -3316 TATTTTGGATATACTATGCTAAATAAAACATATTATTAAAATTAACCTTCACCTGTTTCTTTTCCT  
 -3251 CTTTCAATATGGCTACTAGAGCTTTTTTAAATTGCATTATGTGACTTTATTGGACAGTACCGATTG  
 -3186 AATGCCCTCAACCACATCACCTCACACAGCCACCTCTACCTGTAGTGATCATACCACTTCTTTA  
 -3121 GGCACACTGCCTGCATTAAGGGCAATGAATGCCCTTTTCATCTTCTCCACTAGATGTAGTTTCTTT  
 -3056 TTTCTTTGAGAGCCATCATCACCATCATGGTTGACACCATGAACCTATCTGAAGATGTCAGCCAT  
 -2991 AGACTGCTTGATATTCTACAGGAAAGATCACAGTTTTAAGTGCAATCTACCCATGTTATTAGCAG  
 -2926 TGTGTATCTTTTACACATTACACAGCCTCTCTAAGCCTCATTTCTCTCCTCTGTAAGATGGGGAT  
 -2861 GATAATAACCCATCTCAAATGTTTACTATGAGGATTATTCAAAGAATGGCAAATAGCAAGTGCTT  
 -2796 AATAAATGATAACTAGTACTACCGCCACTACTGTTGTTTTTTATTGTATTAGATTATGAACTCTCT  
 -2731 AAGGACCATTTCGGATGGAGGATAAGAGACCATTTGATGTGGGCAGTGATGAGGCCTTCTGTTG  
 -2666 CACCTGGAAAGGTCAACTATATACAAGCCTGCAAGTCATTCTATAGGAGCAGGCCCCAGTGACCA  
 -2601 GACTCTATAGACTGTCTCCTCTTTTCCTGAGAGGGACAGCCATCTCTAGGTTGACTAACCTCTGAA  
 -2536 GCTCCTTGCAATTGGCTTTTGTGCTATGAGCCATGGATGATTCCAGACTAATCCGAGAATGCTCGT  
 -2471 CAAAACCCCAAGGAATTACTCAAATACTGACATAACAGACATTTTTTGAGTGGAAGAGCCGAGTTT  
 -2406 TTTTAAATATTCTGAAACTCATTGTTTTTTAAATGCATGAGATGGCCAAGGTCTTGCTAAGAGCT  
 -2341 GGCCTGCAAAGCGAAAGGCAGAGAGAATGAAACCCATAGAGAGGCAGAATAACCAGAAAGGTTGG  
 -2276 GACTCGTTTATTTTATAATGTAAATTAGTCTATTATGAAACAATACTTGTTTACTGGTGAAAAT

**FIG. 14E**

-2211 TGGAAAATACAAAGAATAAAAGGAGGAAAAAATCACTCTTTAGTTTCACAAGCCAAATCAAGCC  
 -2146 ACTATTAAAATGGTGGTTTACTTCCTTTTATTAATTTTCTGTACATATTTTGCATAATCATGTT  
 -2081 GTATGTACAATTTTATGTTCTATTTTCAATATTAAGTGGTGTCTTTCAAATTTCTTAATGACAA  
 -2016 AAATAATATATGCTCATAATAGAACATTTTAAATGCAAATAAAACAAAATAAATGTTAAAATTTA  
 -1951 GTAATATTTATTAAATTTTCTCCAAGTGCACGAAATTACAAATGTAACAACCTAATTCCCTAGTG  
 -1886 GCCTAATAACCCTATTTCCAGACCTCTTCTCATTACAAGGAAAACTCATATGCAGATAGTTCTA  
 -1821 AAGGTATGAAGTGAAAAGATAAAGATTTTCTTCCTTGCTGCATCCTCACCCCATCAGCATTATT  
 -1756 CCCCAGGGTAACTACTATTAATAGATAGTAATTCTACCCAAAGGAAAAAATCATATGCATATAAC  
 -1691 AGCATCATATGTATACCTTTCTAGTAACTTACAAAACAAATGATAATATCATATCCTTTCTTATG  
 PvuII (-1580)  
 -1626 TGTATTGCTCTTTTCACTAAATGTATCTGTGATATGTGTCTATATCAGCTGATTGTCCTTTTGA  
 -1561 TGGCTGAATAATATTCATCTTGTCCACGTGATAGTATTACTTGACAAGCTCCCTGCTGATGGAC  
 -1496 ATTTGTCCTTGTACTATGATAGTAATATAATCAACATTTATATATGTTTTGTATGTATCTATAA  
 -1431 TACACATGCACATACACATGCATATTTCTGCAGGGATAGCCATAGTAAATAACTAGTAACGGTAT  
 -1366 TGCAAGTTAAAGGAACAATCTCATTGCTTGAAATTTTAAATTTTGAAATACACTGCCAATTTTCA  
 -1301 TGGTCTCTCCTTGTAAGCTAGTTTGGGCTTTCTCACAGCATGACAGGCTCAGGGCAGTCAGACCA  
 -1236 TCCTGGCCAAAGAGCAGAGTGCCACAGACCACAACCTGCTTCTAATCAGCCATCTTCCCAAAGCCT  
 -1171 TCTCTTTTTTCTATTAATAACTTTGTATGAGATTCCATCTTAATACTTTTCTGTTGTTTGGTCTT  
 -1106 GTAAGAGCTTATTTTCTGAACCAGGAAGTGGTTCAGGGCGGTTTTTCTAACTTCACAGAGCTCC  
 -1041 CTCTTCTGTTAGCTTTTGTGAAATGGTCAAAAACATAGCAGCCTGCCTTCTGAGTTCTCCATCCC  
 -976 ACCCTGGTTGGGCCTTCTCTATCCTTGCTGTGTTGTTTATATCCTGCTGAAGTGTGATTCCACT

**FIG. 14F**

-911 TGTGCAGTTTCTCCTCTGTGTAGGATCAAAAGGGCTGTGGCTGGTTGGTTTGAAAATTTCTTATAC  
-845 CCTAGACTATTCCAGTGCCTTTCAGAAGTTTCCAAGGCCCTCTCACACTAATCTATTATCATATTG  
-779 GGCAAAACTCCTTGCAGTTTCAGCTACTATTCCCTGATTGACTTTTCAGTAAATCTATCTCTCAGT  
-713 CTTTCAGTATCCAAAGAAGATTGGTTCTAGGACCACCATCCCGCTGCCTCCACAGATACCAAATC  
-647 AGAGGATGCTCAATTCCCTCTTATAAAACGTTCCAGTATTTGCATATAATCTGCACATGTATTTCT  
-581 GTATATTTTAAATCATCCCTAGATTACTTATAATACCTGATACAATATAAATGCTAAATAGCTGTA  
-515 ACACTGTATCTTTAAAATTTACATTATTTTTTGTGTTGTATTATTATTTTATTGTATTTTAAA  
-449 AAATATTTTCCATCTACAGTCAGTAGAATCCACGGATACAGAACCTATGGATAGGAAGGACCAACT  
-383 GTATCTTTTAGTGTTTTGAGGTTCTTG

**FIG. 14G**



-356 AATTCTCAGGTCGTTTGCTTTTCCTTTTGCTTTCTCCCAAGTCTTGTTTTACAATTTGCTTTAGTCA  
-291 TTCACTGAAACTTTTAAAAACATTAGAAAACCTCACAGTTTGTAATCTTTTTCCCTATTATATA  
-226 TATCATAAGATAGGAGCTTAAATAAAGAGTTTTAGAACTACTAAAATGTAAATGACATAGGAAA  
-161 ACTGAAAGGGAGAAGTGAAAGTGGGAAATTCCTCTGAATAGAGAGAGGACCATCTCATATAAATA

CAP (-81)

-96 GGCCATACCCACGGAGAAAGGACATTCTAACTGCAACCTTTTGAAGCCTTTTGCTCTGGCACAACA

AUG (1)

-31 GGTAGTAGGCGACACTGTTTCGTGTGTCAAC ATG ACC AAC AAG TGT CTC CTC CAA

25 ATT GCT CTC CTG TTG TGC TTC TCC ACT ACA GCT CTT TCC ATG AGC TAC

73 AAC TTG CTT GGA TTC CTA CAA AGA AGC AGC AAT TTT CAG TGT CAG AAG

121 CTC CTG TGG CAA TTG AAT GGG AGG CTT GAA TAC TGC CTC AAG GAC AGG

PvuII (199)

169 ATG AAC TTT GAC ATC CCT GAG GAG ATT AAG CAG CTG CAG CAG TTC CAG

217 AAG GAG GAC GCC GCA TTG ACC ATC TAT GAG ATG CTC CAG AAC ATC TTT

265 GCT ATT TTC AGA CAA GAT TCA TCT AGC ACT GGC TGG AAT GAG AGT ATT

313 GTT GAG AAC CTC CTG GCT AAT GTC TAT CAT CAG ATA AAC CAT CTG AAG

361 ACA GTC CTG GAA GAA AAA CTG GAG AAA GAA GAT TTC ACC AGG GGA AAA

409 CTC ATG AGC AGT CTG CAC CTG AAA AGA TAT TAT GGG AGG ATT CTG CAT

457 TAC CTG AAG GCC AAG GAG TAC AGT CAC TGT GCC TGG ACC ATA GTC AGA

505 GTG GAA ATC CTA AGG AAC TTT TAC TTC ATT AAC AGA CTT ACA GGT TAC

BglII (565)

553 CTC CGA AAC TGAAGATCTCCTAGCCTGTGCCTCTGGGACTGGACAATTGCTTCAAGCATTCT


615 TCAACCAGCAGATGCTGTTTAAGTGACTGATGGCTAATGTACTGCATATGAAAGGACACTAGAAG

FIG. 15A

680 ATTTTGAAATTTTTATTAAATTATGAGTTATTTTATTTATTTAAATTTTATTTTGGAAAATAAA  
745 TTATTTTGGTGCAAAGTCAACATGGCAGTTTAAATTCGATTTGATTTATATAACCATCCATA  
810 TTATAAAATTGCCAAGTACCTATTAGTTGTTCTTTTAAATATACCTGCAAAGTAGTATACTTT  
875 CTGGCCCCTGCCTTTAAGGAATTTAAAATTCAAGAAAGCCATGATGGAATATATAAGGTAAGAGA  
940 CAATAAGGGGACCTGAACCTTATGGGGGAATAAATATGGCATGAACTGCTGTGGGATTAAAAGAG  
1005 AAAAGGAAAGCTGGAGGGTCTGGAACCTAACCTGGGGTTCCCATTCCTCCTACTGTGTGTTCCAG  
Ball (1099)  
1070 ATTCTCTCATCATAAAGTTAGAATTGAGCTGGCCATCAGGAATAGCCAGAGGAATATGTCAGCTT  
1135 TTGTGTTCTCCCTAACCTTCCCCAGTTATTTGGGGGATCACTTTGCTCCTCGAAAGATTTTAAA  
1200 TAATTATGTGCCCCCACCATCCCTGCAA

**FIG. 15B**

# Activation of the Human $\beta$ -interferon Gene by Homologous Recombination with pINT $\beta$ -1



**FIG. 16**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROTEIN PRODUCTION AND DELIVERY

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 08/406,030 as  
Application Serial No: March 17, 1995  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

			Priority Claimed	
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

08/243,391	May 13, 1994	Pending
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
07/985,586	December 3, 1992	Pending
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
07/911,533	July 10, 1992	
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
07/787,840	November 5, 1991	
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
07/789,188	November 5, 1991	
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
PCT/US93/11704	December 2, 1993	
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
PCT/US92/09627	November 5, 1992	
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)
(Application Serial No.)	(Filing date)	(Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states.

David E. Brook  
James M. Smith  
Leo R. Reynolds  
Richard A. Wise

Registration No. 22,592  
Registration No. 28,043  
Registration No. 20,884  
Registration No. 18,041

Patricia Granahan	Registration No. 32,227
Mary Lou Wakimura	Registration No. 31,804
Thomas O. Hoover	Registration No. 32,470
Alice O. Carroll	Registration No. 33,542
N. Scott Pierce	Registration No. 34,900
Carolyn S. Elmore	Registration No. 37,567

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and

Send correspondence to: Patricia Granahan

Hamilton, Brook, Smith & Reynolds, P.C.

Two Militia Drive, Lexington, Massachusetts 02173

Direct telephone calls to: Patricia Granahan

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

or first inventor Douglas A. Treco

Inventor's

Signature D. A. Treco

Date 4/13/95

Residence

187 Brantwood Road

Arlington, Massachusetts 02174

Citizenship

U.S.

Post Office Address

Same as above

Full name of second joint

inventor, if any Michael W. Hearne

Second Inventor's

Signature Michael W. Hearne

Date 4/13/95

Residence

167 Reed Farm Road

Boxborough, Massachusetts 01719

Citizenship

U.S.

Post Office Address

Same as above

Full name of third joint

inventor, if any Brian M. Hauge

Third Inventor's

Signature B M H

Date 04/13/95

Residence 17 Clifton Avenue

Beverly, Massachusetts 01915

Citizenship U.S.

Post Office Address Same as above

-----

Full name of fourth joint

inventor, if any Richard F Selden

Fourth Inventor's

Signature R F S

Date 04/14/95

Residence 106 Bristol Road

Wellesley, Massachusetts 02181

Citizenship U.S.

Post Office Address Same as above

-----

04/13/95 04/14/95